1 |
(11c)pe2i |
- |
- |
- |
- |
006 1件: 6 💬 |
2 |
(2-chloro-5-[11c]methoxy-n-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) |
- |
- |
- |
- |
006 1件: 6 💬 |
3 |
(3beta, 5beta, 25r)-spirostan-3-ol |
- |
- |
- |
- |
006 1件: 6 💬 |
4 |
(3ß, 5ß, 25r)-spirostan-3-ol |
- |
- |
- |
- |
006 1件: 6 💬 |
5 |
(6s)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol |
- |
- |
- |
- |
006 1件: 6 💬 |
6 |
(minus)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate |
- |
- |
- |
- |
006 1件: 6 💬 |
7 |
(r)-troloxamide quinone |
- |
- |
- |
- |
006 1件: 6 💬 |
8 |
(s)- 2- amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol |
- |
- |
- |
- |
006 1件: 6 💬 |
9 |
(s)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate |
- |
- |
- |
- |
006 1件: 6 💬 |
10 |
0 mg tropicamide |
Tropicamide |
1件: D00397 D00397 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
11 |
0.04 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
12 |
0.08 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
13 |
0.2 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
14 |
0.3 mg tropicamide |
Tropicamide |
1件: D00397 D00397 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
15 |
0.4 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
16 |
0.6 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
17 |
0.8 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
18 |
0.9% sodium chloride |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
006 4件: 6 , 14, 51, 53 💬 |
19 |
0.9% sodium chloride (normal saline) |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
006 1件: 6 💬 |
20 |
00000 |
- |
- |
- |
- |
006 1件: 6 💬 |
21 |
000000 |
- |
- |
- |
- |
006 1件: 6 💬 |
22 |
009-0 |
- |
- |
- |
- |
006 1件: 6 💬 |
23 |
009-1 |
- |
- |
- |
- |
006 1件: 6 💬 |
24 |
009-2 |
- |
- |
- |
- |
006 1件: 6 💬 |
25 |
009-3 |
- |
- |
- |
- |
006 1件: 6 💬 |
26 |
009-4 |
- |
- |
- |
- |
006 1件: 6 💬 |
27 |
009-5 |
- |
- |
- |
- |
006 1件: 6 💬 |
28 |
009-a0 |
- |
- |
- |
- |
006 1件: 6 💬 |
29 |
009-a1 |
- |
- |
- |
- |
006 1件: 6 💬 |
30 |
009-a2 |
- |
- |
- |
- |
006 1件: 6 💬 |
31 |
009-a3 |
- |
- |
- |
- |
006 1件: 6 💬 |
32 |
1 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
33 |
1 mg qd to 7 mg qd pf-06649751 (if de-escalated in parent study) |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
34 |
1 mg tropicamide |
Tropicamide |
1件: D00397 D00397 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
35 |
1. tesofensine (ns 2330) |
Tesofensine |
- |
- |
- |
006 1件: 6 💬 |
36 |
1.0 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
37 |
1.0 mg rasagiline mesylate |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
38 |
1.2 mg lu ae04621 |
- |
- |
- |
- |
006 1件: 6 💬 |
39 |
100 |
- |
- |
- |
- |
006 2件: 6 , 97 💬 |
40 |
11c-methylreboxetine |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
41 |
11c-pbr28 |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
42 |
11c-pib |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
43 |
11c-raclopride |
Raclopride |
- |
- |
- |
006 1件: 6 💬 |
44 |
125 |
- |
- |
- |
- |
006 1件: 6 💬 |
45 |
13n-ammonia |
Ammonia |
1件: D02916 D02916 💬 |
- |
- |
006 2件: 6 , 17 💬 |
46 |
15 mg qd de-escalated to 7 mg qd pf-06649751 in parent study remain at 7 mg qd |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
47 |
15 mg qd pf-06649751 |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
48 |
15o h2o |
- |
- |
- |
- |
006 1件: 6 💬 |
49 |
18-fdtbz |
- |
- |
- |
- |
006 1件: 6 💬 |
50 |
18f florbetaben |
- |
- |
- |
- |
006 1件: 6 💬 |
51 |
18f- dtbz |
- |
- |
- |
- |
006 1件: 6 💬 |
52 |
18f-av-133 |
Florbenazine F-18 |
- |
- |
- |
006 1件: 6 💬 |
53 |
18f-av-45 |
- |
- |
- |
- |
006 2件: 6 , 127 💬 |
54 |
18f-dopa |
- |
- |
- |
- |
006 3件: 6 , 17, 75 💬 |
55 |
18f-dopa pet |
- |
- |
- |
- |
006 1件: 6 💬 |
56 |
18f-dopamne |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
57 |
18f-dtbz |
- |
- |
- |
- |
006 1件: 6 💬 |
58 |
18f-dtbz av-133 |
- |
- |
- |
- |
006 1件: 6 💬 |
59 |
18f-fdg |
Fludeoxyglucose (18F) |
- |
- |
- |
005 12件: 5 , 6 , 7 , 13, 41, 46, 53, 84, 85, 96, 127, 300 💬 |
60 |
1[(6- allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- |
- |
- |
- |
- |
006 1件: 6 💬 |
61 |
1[(6- allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea |
- |
- |
- |
- |
006 1件: 6 💬 |
62 |
1[(6- allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- |
- |
- |
- |
- |
006 1件: 6 💬 |
63 |
1[(6- allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea |
- |
- |
- |
- |
006 1件: 6 💬 |
64 |
2 mg perampanel |
Perampanel |
1件: D08964 D08964 💬 |
GRIA1 4件: GRIA1, GRIA2, GRIA3, GRIA4 💬 |
Amphetamine addiction 16件: Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway |
006 1件: 6 💬 |
65 |
2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide |
- |
- |
- |
- |
006 1件: 6 💬 |
66 |
2-[[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]-4- piperidinyl]-5-oxo-2-pyrrolidinyl]carbonyl]amino]- n,n,6-trimethyl-4-pyridinecarboxamide,dihydrochloride |
- |
- |
- |
- |
006 2件: 6 , 162 💬 |
67 |
200 mg bia 6-512 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
68 |
207-3120 |
- |
- |
- |
- |
006 1件: 6 💬 |
69 |
240mg amantadine hcl er tablets |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
70 |
25 mg bia9 1067 |
- |
- |
- |
- |
006 1件: 6 💬 |
71 |
25 mg ongentys |
- |
- |
- |
- |
006 1件: 6 💬 |
72 |
25330 |
- |
- |
- |
- |
006 1件: 6 💬 |
73 |
3 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
74 |
3 mg qd to 7 mg qd pf-06649751 (de-escalated in parent study) |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
75 |
3 mg tropicamide |
Tropicamide |
1件: D00397 D00397 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
76 |
3- (9,10- didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate |
- |
- |
- |
- |
006 1件: 6 💬 |
77 |
3-(3,4-dihydroxyphenyl)-l-alanine |
Alanine |
1件: D00012 D00012 💬 |
- |
- |
006 1件: 6 💬 |
78 |
320mg amantadine hcl er tablets |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
79 |
4 mg perampanel |
Perampanel |
1件: D08964 D08964 💬 |
GRIA1 4件: GRIA1, GRIA2, GRIA3, GRIA4 💬 |
Amphetamine addiction 16件: Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway |
006 1件: 6 💬 |
80 |
50 mg bia 9 1067 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
81 |
50 mg ongentys |
- |
- |
- |
- |
006 1件: 6 💬 |
82 |
6abeta - apomorphine-10,11-diol hydrochloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
83 |
6aß - apomorphine-10,11-diol hydrochloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
84 |
7 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
85 |
7 mg qd to 7 mg qd pf-06649751 (de-escalated in parent study) |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
86 |
7-beta-hydroxyepiandrosterone |
7-beta-Hydroxyepiandrosterone |
- |
- |
- |
006 1件: 6 💬 |
87 |
75 |
- |
- |
- |
- |
006 1件: 6 💬 |
88 |
8-ohdg |
8-hydroxy-2'-deoxyguanosine |
- |
- |
- |
006 1件: 6 💬 |
89 |
[11c]pbr28 |
- |
- |
- |
- |
006 1件: 6 💬 |
90 |
[11c]pxt012253 |
- |
- |
- |
- |
006 1件: 6 💬 |
91 |
[11c]smw139 |
- |
- |
- |
- |
006 1件: 6 💬 |
92 |
[123i] 5-ia |
- |
- |
- |
- |
006 1件: 6 💬 |
93 |
[123i] ibvm and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
94 |
[123i] mzint injection and serial dynamic spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
95 |
[123i]-ibvm |
- |
- |
- |
- |
006 1件: 6 💬 |
96 |
[123i]b-cit |
- |
- |
- |
- |
006 1件: 6 💬 |
97 |
[123i]b-cit spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
98 |
[123i]beta cit |
- |
- |
- |
- |
006 1件: 6 💬 |
99 |
[123i]beta cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
100 |
[123i]beta-cit |
- |
- |
- |
- |
006 1件: 6 💬 |
101 |
[123i]beta-cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
102 |
[123i]clinde |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
103 |
[123i]mni-420 |
- |
- |
- |
- |
006 2件: 6 , 8 💬 |
104 |
[123i]ß cit |
- |
- |
- |
- |
006 1件: 6 💬 |
105 |
[123i]ß cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
106 |
[123i]ß-cit |
- |
- |
- |
- |
006 1件: 6 💬 |
107 |
[123i]ß-cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
108 |
[14c]-bia 9-1067 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
109 |
[15o]h2o |
- |
- |
- |
- |
006 1件: 6 💬 |
110 |
[18f] cfpypb |
- |
- |
- |
- |
006 1件: 6 💬 |
111 |
[18f] lbt-999 |
- |
- |
- |
- |
006 1件: 6 💬 |
112 |
[18f] lbt-999 pet |
- |
- |
- |
- |
006 1件: 6 💬 |
113 |
[18f] pbr06 |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
114 |
[18f]-(e)-n-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane |
- |
- |
- |
- |
006 1件: 6 💬 |
115 |
[18f]-feppa |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
116 |
[18f]dpa-714 pet scan |
- |
- |
- |
- |
006 1件: 6 💬 |
117 |
[18f]fdopa |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
118 |
[18f]fdopa pet/ct |
- |
- |
- |
- |
006 1件: 6 💬 |
119 |
[18f]fe-pe2i |
- |
- |
- |
- |
006 1件: 6 💬 |
120 |
[18f]fpeb |
- |
- |
- |
- |
006 3件: 6 , 8 , 206 💬 |
121 |
[18f]mk-9470 |
- |
- |
- |
- |
006 1件: 6 💬 |
122 |
[18f]mni-1126 |
- |
- |
- |
- |
006 1件: 6 💬 |
123 |
[18f]mppf |
- |
- |
- |
- |
006 1件: 6 💬 |
124 |
[18f]nos |
- |
- |
- |
- |
006 1件: 6 💬 |
125 |
[18f]p17-059 |
- |
- |
- |
- |
006 1件: 6 💬 |
126 |
[18f]pi-2620 |
- |
- |
- |
- |
006 2件: 6 , 127 💬 |
127 |
[18f]t807 ([18f]mni-777) |
- |
- |
- |
- |
005 2件: 5 , 6 💬 |
128 |
[21cfr640.30] plasma from 18 - 25 year old volunteer donors |
- |
- |
- |
- |
006 1件: 6 💬 |
129 |
[abbv-951] |
- |
- |
- |
- |
006 1件: 6 💬 |
130 |
[f-18] fluorodopa positron emission tomography |
- |
- |
- |
- |
006 1件: 6 💬 |
131 |
[jnj31-31001074] |
- |
- |
- |
- |
006 1件: 6 💬 |
132 |
[na] |
- |
- |
- |
- |
006 7件: 6 , 11, 35, 46, 53, 65, 299 💬 |
133 |
A-dopamine |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
134 |
Aav2-gdnf |
- |
- |
- |
- |
006 1件: 6 💬 |
135 |
Ab1010 |
- |
- |
- |
- |
002 6件: 2 , 5 , 6 , 13, 46, 96 💬 |
136 |
Abbv-0805 |
- |
- |
- |
- |
006 1件: 6 💬 |
137 |
Abbv-951 |
- |
- |
- |
- |
006 1件: 6 💬 |
138 |
Abt-slv187 |
- |
- |
- |
- |
006 1件: 6 💬 |
139 |
Acamprosate |
Acamprosate |
2件: D02780 D02780, D07058 D07058 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 2件: 6 , 206 💬 |
140 |
Accordion pill carbidopa/levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
141 |
Accordion pill ¿ carbidopa/levodopa 50/400 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
142 |
Accordion pill ¿ carbidopa/levodopa 50/500 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
143 |
Accordion pill? carbidopa/levodopa 50/400 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
144 |
Accordion pill? carbidopa/levodopa 50/500 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
145 |
Accordion pill™ carbidopa/levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
146 |
Accordion pill™ carbidopa/levodopa 50/400 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
147 |
Accordion pill™ carbidopa/levodopa 50/500 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
148 |
Acetate |
Acetate |
- |
- |
- |
001 43件: 1 , 2 , 6 , 10, 13, 35, 40, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 227, 235, 265, 288, 298, 299 💬 |
149 |
Acetylcysteine |
Acetylcysteine |
1件: D00221 D00221 💬 |
- |
- |
006 16件: 6 , 13, 19, 20, 34, 49, 51, 58, 85, 94, 111, 164, 193, 233, 298, 299 💬 |
150 |
Acp-103 |
- |
- |
- |
- |
006 1件: 6 💬 |
151 |
Acr325 |
ACR325 |
- |
- |
- |
006 1件: 6 💬 |
152 |
Active comparator |
- |
- |
- |
- |
006 2件: 6 , 46 💬 |
153 |
Active drug (biib014) at 10, 30, 100, or 300 mg once daily. |
- |
- |
- |
- |
006 1件: 6 💬 |
154 |
Active drug: pimavanserin 17mg (2 strength tablets) |
Pimavanserin |
- |
- |
- |
006 1件: 6 💬 |
155 |
Active investigational treatment ent-01 |
- |
- |
- |
- |
006 1件: 6 💬 |
156 |
Ad-810n (zonisamide) |
Zonisamide |
1件: D00538 D00538 💬 |
CACNA1G 8件: CACNA1G, CACNA1H, CACNA1I, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 11件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dopaminergic synapse, GnRH secretion, MAPK signaling pathway, Taste transduction, Type II diabetes mellitus |
006 1件: 6 💬 |
157 |
Adjuvant without active component |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
158 |
Administration of stable isotope-labelled leucine- |
Leucine |
1件: D00030 D00030 💬 |
- |
- |
006 1件: 6 💬 |
159 |
Ads-5102 |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
160 |
Ads-5102 (extended release amantadine hcl) |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
161 |
Adx48621 |
- |
- |
- |
- |
006 1件: 6 💬 |
162 |
Affitope® pd01a |
- |
- |
- |
- |
006 1件: 6 💬 |
163 |
Affitope® pd01a + adjuvant |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
164 |
Afq056 |
- |
- |
- |
- |
006 3件: 6 , 8 , 206 💬 |
165 |
Afq056 with l-dopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
166 |
Afq065 |
- |
- |
- |
- |
006 1件: 6 💬 |
167 |
Agomelatine |
Agomelatine |
1件: D02578 D02578 💬 |
HTR2C 3件: HTR2C, MTNR1A, MTNR1B 💬 |
Calcium signaling pathway 6件: Calcium signaling pathway, Circadian entrainment, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
006 1件: 6 💬 |
168 |
Agomelatine or piacebo |
Agomelatine |
1件: D02578 D02578 💬 |
HTR2C 3件: HTR2C, MTNR1A, MTNR1B 💬 |
Calcium signaling pathway 6件: Calcium signaling pathway, Circadian entrainment, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
006 1件: 6 💬 |
169 |
Aha |
- |
- |
- |
- |
006 1件: 6 💬 |
170 |
Akst4290 |
- |
- |
- |
- |
006 2件: 6 , 162 💬 |
171 |
Al |
- |
- |
- |
- |
005 9件: 5 , 6 , 7 , 28, 51, 67, 86, 114, 127 💬 |
172 |
Alanine |
Alanine |
1件: D00012 D00012 💬 |
- |
- |
006 4件: 6 , 13, 298, 299 💬 |
173 |
Allogeneic bone marrow-derived mscs (1 x 10 6 msc/kg) |
- |
- |
- |
- |
006 1件: 6 💬 |
174 |
Allogeneic bone marrow-derived mscs (10 x 10 6 msc/kg) |
- |
- |
- |
- |
006 1件: 6 💬 |
175 |
Allogeneic bone marrow-derived mscs (3 x 10 6 msc/kg) |
- |
- |
- |
- |
006 1件: 6 💬 |
176 |
Allogeneic bone marrow-derived mscs (6 x 10 6 msc/kg) |
- |
- |
- |
- |
006 1件: 6 💬 |
177 |
Allopurinol |
Allopurinol |
1件: D00224 D00224 💬 |
XDH 1件: XDH 💬 |
Caffeine metabolism 5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
006 6件: 6 , 46, 57, 66, 96, 97 💬 |
178 |
Altropane |
Altropane |
- |
- |
- |
006 1件: 6 💬 |
179 |
Altropane® |
Altropane |
- |
- |
- |
006 1件: 6 💬 |
180 |
Amantadin-ratiopharm 100mg |
- |
- |
- |
- |
006 1件: 6 💬 |
181 |
Amantadine |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 4件: 6 , 8 , 13, 127 💬 |
182 |
Amantadine 300 mg |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
183 |
Amantadine hcl er |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
184 |
Amantadine hcl extended release |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
185 |
Amantadine hcl extended release capsule |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
186 |
Amantadine hydrochloride |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
187 |
Amantadine hydrochloride (hcl) |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
188 |
Amantadine sulfate |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
189 |
Ambrosan 60mg tablets |
- |
- |
- |
- |
006 1件: 6 💬 |
190 |
Ambroxol |
Ambroxol |
1件: D07442 D07442 💬 |
- |
- |
006 2件: 6 , 19 💬 |
191 |
Ambroxol hydrochloride |
Ambroxol |
1件: D07442 D07442 💬 |
- |
- |
006 1件: 6 💬 |
192 |
Ammonia |
Ammonia |
1件: D02916 D02916 💬 |
- |
- |
006 4件: 6 , 17, 86, 88 💬 |
193 |
Amoxicillin |
Amoxicillin |
3件: D00229 D00229, D02925 D02925, D07452 D07452 💬 |
- |
- |
006 7件: 6 , 46, 63, 96, 97, 222, 299 💬 |
194 |
Ampreloxetine |
Ampreloxetine |
1件: D11688 D11688 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6 , 17 💬 |
195 |
Ampreloxetine chydrochloride |
Ampreloxetine |
1件: D11688 D11688 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6 , 17 💬 |
196 |
Ampreloxetine hydrochloride |
Ampreloxetine |
1件: D11688 D11688 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6 , 17 💬 |
197 |
Ampyra |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
198 |
Ampyra first, |
- |
- |
- |
- |
006 1件: 6 💬 |
199 |
Anavex2-73 |
- |
- |
- |
- |
006 2件: 6 , 156 💬 |
200 |
Anhydrous carbidopa |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
201 |
Anti-parkinson medication |
- |
- |
- |
- |
005 5件: 5 , 6 , 7 , 8 , 17 💬 |
202 |
Antiparkinsonian agent(s) |
- |
- |
- |
- |
006 1件: 6 💬 |
203 |
Ap |
- |
- |
- |
- |
002 4件: 2 , 6 , 13, 299 💬 |
204 |
Ap-cd/ld |
- |
- |
- |
- |
006 1件: 6 💬 |
205 |
Ap09004 |
- |
- |
- |
- |
006 1件: 6 💬 |
206 |
Apl-130277 |
- |
- |
- |
- |
006 1件: 6 💬 |
207 |
Aplindore |
Aplindore |
- |
- |
- |
006 1件: 6 💬 |
208 |
Aplindore mr tablets |
Aplindore |
- |
- |
- |
006 1件: 6 💬 |
209 |
Apo-go |
- |
- |
- |
- |
006 1件: 6 💬 |
210 |
Apo-go® |
- |
- |
- |
- |
006 1件: 6 💬 |
211 |
Apokinon |
- |
- |
- |
- |
006 1件: 6 💬 |
212 |
Apokyn |
- |
- |
- |
- |
006 1件: 6 💬 |
213 |
Apomor |
- |
- |
- |
- |
006 1件: 6 💬 |
214 |
Apomorp |
- |
- |
- |
- |
006 1件: 6 💬 |
215 |
Apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
216 |
Apomorphine 0.25% (2.5mg/ml) |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
217 |
Apomorphine hcl injection |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
218 |
Apomorphine hydrochloride |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
219 |
Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
220 |
Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
221 |
Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
222 |
Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
223 |
Apomorphine hydrochloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
224 |
Apomorphine hydrocloride |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
225 |
Apomorphine hydrocloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
226 |
Apomorphine infusion |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
227 |
Apomorphine nasal powder |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
228 |
Aporon |
- |
- |
- |
- |
006 1件: 6 💬 |
229 |
Aqw051 |
- |
- |
- |
- |
006 1件: 6 💬 |
230 |
Aricept |
- |
- |
- |
- |
006 4件: 6 , 13, 78, 124 💬 |
231 |
Aricept 5 mg-filmtabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
232 |
Aricept 5mg-filmtabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
233 |
Aripiprazole |
Aripiprazole |
1件: D01164 D01164 💬 |
DRD2 4件: DRD2, DRD3, HTR1A, HTR2A 💬 |
Alcoholism 12件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
006 2件: 6 , 206 💬 |
234 |
Armodafinil |
Armodafinil |
1件: D03215 D03215 💬 |
SLC6A3 1件: SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 3件: 6 , 13, 84 💬 |
235 |
Artane |
- |
- |
- |
- |
006 1件: 6 💬 |
236 |
As2 |
- |
- |
- |
- |
006 1件: 6 💬 |
237 |
Asyn mab |
- |
- |
- |
- |
006 1件: 6 💬 |
238 |
At 10 |
- |
- |
- |
- |
006 1件: 6 💬 |
239 |
Atm fog in pd |
- |
- |
- |
- |
006 1件: 6 💬 |
240 |
Atomoxetine |
Atomoxetine |
2件: D02574 D02574, D07473 D07473 💬 |
SLC6A2 1件: SLC6A2 💬 |
Synaptic vesicle cycle 1件: Synaptic vesicle cycle |
006 3件: 6 , 8 , 13 💬 |
241 |
Atypical antipsychotics |
- |
- |
- |
- |
006 1件: 6 💬 |
242 |
Autologous mesenchymal stem cells |
- |
- |
- |
- |
002 5件: 2 , 6 , 13, 17, 46 💬 |
243 |
Av-101 |
AV-101 |
- |
- |
- |
006 1件: 6 💬 |
244 |
Avalox |
- |
- |
- |
- |
006 1件: 6 💬 |
245 |
Avalox - 400 mg compresse rivestite con film 5 compresse in blister pp/al |
- |
- |
- |
- |
006 1件: 6 💬 |
246 |
Ave8112 |
- |
- |
- |
- |
006 1件: 6 💬 |
247 |
Avp-923 |
- |
- |
- |
- |
002 3件: 2 , 6 , 13 💬 |
248 |
Avp-923-45 |
- |
- |
- |
- |
006 1件: 6 💬 |
249 |
Azathioprine |
Azathioprine |
2件: D00238 D00238, D03033 D03033 💬 |
- |
- |
006 20件: 6 , 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 94, 95, 96, 97, 162 💬 |
250 |
Azd3241 |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
251 |
Azd3241 300 mg bid |
- |
- |
- |
- |
006 1件: 6 💬 |
252 |
Azd3241 600 mg bid |
- |
- |
- |
- |
006 1件: 6 💬 |
253 |
Azd3241 alternative titration scheme with formulation 1 or 2 |
- |
- |
- |
- |
006 1件: 6 💬 |
254 |
Azd3241 er formulation 1 |
- |
- |
- |
- |
006 1件: 6 💬 |
255 |
Azd3241 extended release tablets 100 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
256 |
Azd3241 extended release tablets 25 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
257 |
Azilect |
- |
- |
- |
- |
002 4件: 2 , 5 , 6 , 17 💬 |
258 |
Azilect 1 mg comprimidos |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
259 |
Azilect 1mg |
- |
- |
- |
- |
006 1件: 6 💬 |
260 |
Azilect® |
- |
- |
- |
- |
006 1件: 6 💬 |
261 |
B-cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
262 |
B6, b12, l-methylfolate |
Levomefolic acid |
1件: D09353 D09353 💬 |
- |
- |
006 1件: 6 💬 |
263 |
Balance |
Isoxaflutole |
- |
- |
- |
005 9件: 5 , 6 , 13, 46, 81, 113, 122, 149, 299 💬 |
264 |
Band |
- |
- |
- |
- |
006 2件: 6 , 97 💬 |
265 |
Bavisant |
Bavisant |
1件: D09870 D09870 💬 |
HRH3 1件: HRH3 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
266 |
Bavisant dihydrochloride monohydrate |
Bavisant |
1件: D09870 D09870 💬 |
HRH3 1件: HRH3 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
267 |
Bavisant hydrochloride monohydrate |
Bavisant |
1件: D09870 D09870 💬 |
HRH3 1件: HRH3 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
268 |
Beam |
Tricyclazole |
- |
- |
- |
006 2件: 6 , 51 💬 |
269 |
Bee venom |
- |
- |
- |
- |
006 1件: 6 💬 |
270 |
Behavioral: assessment of cognition |
- |
- |
- |
- |
006 1件: 6 💬 |
271 |
Behavioral: assessment of depression |
- |
- |
- |
- |
006 1件: 6 💬 |
272 |
Behavioral: assessment of motor and non-motors symptoms of pd evaluation of hyper- and hypodopaminergic behaviors |
- |
- |
- |
- |
006 1件: 6 💬 |
273 |
Behavioral: assessment of quality of life |
- |
- |
- |
- |
006 1件: 6 💬 |
274 |
Behavioral: assessment of severity of icd (impulse control disorders) |
- |
- |
- |
- |
006 1件: 6 💬 |
275 |
Behavioral: assessment of severity of parkinson disease |
- |
- |
- |
- |
006 1件: 6 💬 |
276 |
Behavioral: attention control |
- |
- |
- |
- |
006 1件: 6 💬 |
277 |
Behavioral: augmented reality multi-modal training |
- |
- |
- |
- |
006 1件: 6 💬 |
278 |
Behavioral: balance & strengthening exercises |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
279 |
Behavioral: balance training |
Isoxaflutole |
- |
- |
- |
006 2件: 6 , 13 💬 |
280 |
Behavioral: bci-fit active querying |
- |
- |
- |
- |
002 3件: 2 , 6 , 17 💬 |
281 |
Behavioral: bci-fit adaptive signal modeling |
- |
- |
- |
- |
002 3件: 2 , 6 , 17 💬 |
282 |
Behavioral: bci-fit language modeling |
- |
- |
- |
- |
002 3件: 2 , 6 , 17 💬 |
283 |
Behavioral: bci-fit multi-modal access |
- |
- |
- |
- |
002 3件: 2 , 6 , 17 💬 |
284 |
Behavioral: brisk walking and balance training |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
285 |
Behavioral: building better caregivers workshop |
- |
- |
- |
- |
006 1件: 6 💬 |
286 |
Behavioral: cbt and sleep hygiene |
- |
- |
- |
- |
006 1件: 6 💬 |
287 |
Behavioral: co-op treatment protocol |
- |
- |
- |
- |
006 1件: 6 💬 |
288 |
Behavioral: cognitive and behavioral experimental tasks |
- |
- |
- |
- |
006 2件: 6 , 127 💬 |
289 |
Behavioral: combined balance and brisk walking training |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
290 |
Behavioral: conservative measures for orthostatic hypotension |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
291 |
Behavioral: dexterity |
- |
- |
- |
- |
006 1件: 6 💬 |
292 |
Behavioral: dual task |
- |
- |
- |
- |
006 1件: 6 💬 |
293 |
Behavioral: ecocapture |
- |
- |
- |
- |
006 2件: 6 , 127 💬 |
294 |
Behavioral: emotion assessment |
- |
- |
- |
- |
006 1件: 6 💬 |
295 |
Behavioral: exercise |
- |
- |
- |
- |
006 3件: 6 , 265, 299 💬 |
296 |
Behavioral: exercise only |
- |
- |
- |
- |
006 1件: 6 💬 |
297 |
Behavioral: exercise+multi-modal sensory feedback (mmsf) |
- |
- |
- |
- |
006 1件: 6 💬 |
298 |
Behavioral: flexibility and strengthening exercise |
- |
- |
- |
- |
006 1件: 6 💬 |
299 |
Behavioral: gait and balance |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
300 |
Behavioral: gait and balance training program |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
301 |
Behavioral: healthy age-matched controls |
- |
- |
- |
- |
006 1件: 6 💬 |
302 |
Behavioral: icm_apathy_tasks |
- |
- |
- |
- |
006 2件: 6 , 127 💬 |
303 |
Behavioral: levodopa or acupuncture |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
304 |
Behavioral: low-impact exercise control |
- |
- |
- |
- |
006 1件: 6 💬 |
305 |
Behavioral: memory |
- |
- |
- |
- |
006 1件: 6 💬 |
306 |
Behavioral: participant open-response writing |
- |
- |
- |
- |
006 1件: 6 💬 |
307 |
Behavioral: participant self-assessment surveys |
- |
- |
- |
- |
006 1件: 6 💬 |
308 |
Behavioral: pat sessions |
- |
- |
- |
- |
006 1件: 6 💬 |
309 |
Behavioral: pelvic floor muscle exercise-based behavioral therapy |
- |
- |
- |
- |
006 1件: 6 💬 |
310 |
Behavioral: phonation |
- |
- |
- |
- |
006 1件: 6 💬 |
311 |
Behavioral: physical exam and updrs part iii assessment |
- |
- |
- |
- |
006 1件: 6 💬 |
312 |
Behavioral: physical therapy |
- |
- |
- |
- |
006 1件: 6 💬 |
313 |
Behavioral: resistance training |
- |
- |
- |
- |
006 1件: 6 💬 |
314 |
Behavioral: rest |
- |
- |
- |
- |
006 1件: 6 💬 |
315 |
Behavioral: role of dopamine |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
316 |
Behavioral: single task |
- |
- |
- |
- |
006 1件: 6 💬 |
317 |
Behavioral: strength training |
- |
- |
- |
- |
006 1件: 6 💬 |
318 |
Behavioral: stretching |
- |
- |
- |
- |
006 1件: 6 💬 |
319 |
Behavioral: tai chi |
- |
- |
- |
- |
006 1件: 6 💬 |
320 |
Behavioral: traditional multi-modal training |
- |
- |
- |
- |
006 1件: 6 💬 |
321 |
Behavioral: upper limb exercise |
- |
- |
- |
- |
006 1件: 6 💬 |
322 |
Ben-2001 |
- |
- |
- |
- |
006 1件: 6 💬 |
323 |
Benserazide |
Benserazide |
1件: D03082 D03082 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
324 |
Benserazide hydrochloride |
Benserazide |
1件: D03082 D03082 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
325 |
Benzofuran |
Benzofuran |
- |
- |
- |
006 1件: 6 💬 |
326 |
Berachin |
- |
- |
- |
- |
006 1件: 6 💬 |
327 |
Best medical treatment |
- |
- |
- |
- |
006 1件: 6 💬 |
328 |
Best médical treatment |
- |
- |
- |
- |
006 1件: 6 💬 |
329 |
Betaquik mct supplement |
- |
- |
- |
- |
006 1件: 6 💬 |
330 |
Better |
- |
- |
- |
- |
006 1件: 6 💬 |
331 |
Bf 2.649 |
- |
- |
- |
- |
006 1件: 6 💬 |
332 |
Bf 2.649 10 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
333 |
Bf 2.649 20 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
334 |
Bf 2.649 40 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
335 |
Bf 2.649 5 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
336 |
Bf2.649 |
- |
- |
- |
- |
006 1件: 6 💬 |
337 |
Bf2.649 (pitolisant) |
Pitolisant |
1件: D10749 D10749 💬 |
HRH3 1件: HRH3 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
338 |
Bi-sifrol® |
- |
- |
- |
- |
006 1件: 6 💬 |
339 |
Bia |
BIA |
- |
- |
- |
006 2件: 6 , 86 💬 |
340 |
Bia 3-202 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
341 |
Bia 3-202 (200 mg) |
BIA |
- |
- |
- |
006 1件: 6 💬 |
342 |
Bia 6-512 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
343 |
Bia 6-512 100 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
344 |
Bia 6-512 100 mg dose |
BIA |
- |
- |
- |
006 1件: 6 💬 |
345 |
Bia 6-512 200 mg dose |
BIA |
- |
- |
- |
006 1件: 6 💬 |
346 |
Bia 6-512 25 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
347 |
Bia 6-512 25 mg dose |
BIA |
- |
- |
- |
006 1件: 6 💬 |
348 |
Bia 6-512 400 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
349 |
Bia 6-512 50 mg dose |
BIA |
- |
- |
- |
006 1件: 6 💬 |
350 |
Bia 9-1067 |
BIA |
- |
- |
- |
006 1件: 6 💬 |
351 |
Bia 9-1067 (test) |
BIA |
- |
- |
- |
006 1件: 6 💬 |
352 |
Bia 9-1067 15 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
353 |
Bia 9-1067 25 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
354 |
Bia 9-1067 30 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
355 |
Bia 9-1067 5 mg |
BIA |
- |
- |
- |
006 1件: 6 💬 |
356 |
Bia 9-1067 micronized |
BIA |
- |
- |
- |
006 1件: 6 💬 |
357 |
Bia 9-1067 non-micronized |
BIA |
- |
- |
- |
006 1件: 6 💬 |
358 |
Biib014 |
- |
- |
- |
- |
006 1件: 6 💬 |
359 |
Biib054 |
- |
- |
- |
- |
006 1件: 6 💬 |
360 |
Biib094 |
- |
- |
- |
- |
006 1件: 6 💬 |
361 |
Bisphosphonates |
- |
- |
- |
- |
006 2件: 6 , 274 💬 |
362 |
Bone marrow derived mesenchymal stem cells |
- |
- |
- |
- |
006 2件: 6 , 60 💬 |
363 |
Bont-a |
- |
- |
- |
- |
006 1件: 6 💬 |
364 |
Botox |
- |
- |
- |
- |
002 6件: 2 , 6 , 13, 51, 149, 226 💬 |
365 |
Botulinum toxin |
- |
- |
- |
- |
006 3件: 6 , 13, 149 💬 |
366 |
Botulinum toxin type a |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
002 10件: 2 , 5 , 6 , 7 , 13, 15, 17, 70, 113, 149 💬 |
367 |
Botulinum toxin type b |
Botulinum Toxin Type B |
1件: D02735 D02735 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
002 3件: 2 , 6 , 51 💬 |
368 |
Botulinum toxin type b (myobloc) |
Botulinum Toxin Type B |
1件: D02735 D02735 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
002 2件: 2 , 6 💬 |
369 |
Botulinum toxin: xeomin |
- |
- |
- |
- |
006 1件: 6 💬 |
370 |
Bromocriptine |
Bromocriptine |
2件: D00780 D00780, D03165 D03165 💬 |
DRD2 2件: DRD2, PRL 💬 |
Alcoholism 12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
006 2件: 6 , 74 💬 |
371 |
Bromocriptine and other dopamine agonists |
Bromocriptine |
4件: D00633 D00633, D00780 D00780, D03165 D03165, D07870 D07870 💬 |
DRD1 6件: DRD1, DRD2, DRD3, DRD4, DRD5, PRL 💬 |
Alcoholism 15件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
372 |
Btrx-246040 |
BTRX-246040 |
- |
- |
- |
006 1件: 6 💬 |
373 |
Btx-a |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
006 1件: 6 💬 |
374 |
Bumetanide |
Bumetanide |
1件: D00247 D00247 💬 |
SLC12A2 1件: SLC12A2 💬 |
Pancreatic secretion 3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection |
006 2件: 6 , 158 💬 |
375 |
Bumetanide white, oblong, scored tablet |
Bumetanide |
1件: D00247 D00247 💬 |
SLC12A2 1件: SLC12A2 💬 |
Pancreatic secretion 3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection |
006 1件: 6 💬 |
376 |
Bupleurum+ginkgo |
Ginkgo biloba |
- |
- |
- |
006 1件: 6 💬 |
377 |
Buspirone |
Buspirone |
2件: D00702 D00702, D07593 D07593 💬 |
DRD2 2件: DRD2, HTR1A 💬 |
Alcoholism 10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
006 2件: 6 , 51 💬 |
378 |
Buspirone hydrochloride |
Buspirone |
2件: D00702 D00702, D07593 D07593 💬 |
DRD2 2件: DRD2, HTR1A 💬 |
Alcoholism 10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
379 |
Butylphthalide |
Butylphthalide |
- |
- |
- |
002 4件: 2 , 6 , 18, 22 💬 |
380 |
Bydureon |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
381 |
Bydureon 2 mg powder and solvent for prolonged-release suspension |
- |
- |
- |
- |
006 1件: 6 💬 |
382 |
Byetta |
- |
- |
- |
- |
006 2件: 6 , 193 💬 |
383 |
Byetta 5 micrograms |
- |
- |
- |
- |
006 1件: 6 💬 |
384 |
Cabaser |
- |
- |
- |
- |
006 1件: 6 💬 |
385 |
Cabaseril |
- |
- |
- |
- |
006 1件: 6 💬 |
386 |
Cabaseril, 1,0 mg tablette |
- |
- |
- |
- |
006 1件: 6 💬 |
387 |
Cabaseril, 2,0 mg tablette |
- |
- |
- |
- |
006 1件: 6 💬 |
388 |
Cabergolina |
Cabergoline |
1件: D00987 D00987 💬 |
DRD2 2件: DRD2, PRL 💬 |
Alcoholism 12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
389 |
Cabergoline |
Cabergoline |
1件: D00987 D00987 💬 |
DRD2 2件: DRD2, PRL 💬 |
Alcoholism 12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
006 3件: 6 , 74, 75 💬 |
390 |
Caffeine |
Caffeine |
2件: D00528 D00528, D01453 D01453 💬 |
ADORA1 11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 |
Alcoholism 22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
002 9件: 2 , 6 , 13, 21, 46, 78, 96, 97, 265 💬 |
391 |
Caffeine 100-200 mg bid |
Caffeine |
2件: D00528 D00528, D01453 D01453 💬 |
ADORA1 11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 |
Alcoholism 22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
392 |
Caffeine alkaloid |
Caffeine |
2件: D00528 D00528, D01453 D01453 💬 |
ADORA1 11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 |
Alcoholism 22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
393 |
Calcium |
Calcium |
- |
- |
- |
006 27件: 6 , 13, 19, 46, 49, 51, 53, 56, 68, 75, 79, 84, 93, 94, 95, 96, 97, 186, 214, 215, 222, 224, 235, 265, 274, 298, 299 💬 |
394 |
Cannabidiol |
Cannabidiol |
1件: D10915 D10915 💬 |
CNR1 2件: CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
006 17件: 6 , 8 , 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 226, 271 💬 |
395 |
Cannabidiol (cbd) |
Cannabidiol |
1件: D10915 D10915 💬 |
CNR1 2件: CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
006 6件: 6 , 140, 144, 145, 156, 158 💬 |
396 |
Cannabis |
Medical Cannabis |
- |
- |
- |
002 8件: 2 , 6 , 13, 46, 90, 96, 97, 271 💬 |
397 |
Cannabis oil |
Medical Cannabis |
- |
- |
- |
006 1件: 6 💬 |
398 |
Cannabis, medical |
Medical Cannabis |
- |
- |
- |
002 5件: 2 , 6 , 13, 96, 97 💬 |
399 |
Capsaicin |
Capsaicin |
1件: D00250 D00250 💬 |
TRPV1 1件: TRPV1 💬 |
Inflammatory mediator regulation of TRP channels 2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
002 5件: 2 , 6 , 19, 86, 226 💬 |
400 |
Capsaicin vapor |
Capsaicin |
1件: D00250 D00250 💬 |
TRPV1 1件: TRPV1 💬 |
Inflammatory mediator regulation of TRP channels 2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
401 |
Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
402 |
Capture |
Bifenthrin |
- |
- |
- |
006 2件: 6 , 46 💬 |
403 |
Carbidopa |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
002 9件: 2 , 4 , 6 , 13, 17, 90, 140, 164, 201 💬 |
404 |
Carbidopa (fu) |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
405 |
Carbidopa 20 mg |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
406 |
Carbidopa 200mg oral dose |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 2件: 6 , 17 💬 |
407 |
Carbidopa 27.5 mg |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
408 |
Carbidopa 65 mg capsule |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
409 |
Carbidopa and levodopa 25mg/100mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
410 |
Carbidopa and levodopa tablets, usp |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
411 |
Carbidopa anidra |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
412 |
Carbidopa fu |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
413 |
Carbidopa inn |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
414 |
Carbidopa levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
415 |
Carbidopa monohydrate |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
416 |
Carbidopa, levodopa, entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
417 |
Carbidopa- levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
418 |
Carbidopa-4'-monophosphate |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
419 |
Carbidopa-levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
002 3件: 2 , 4 , 6 💬 |
420 |
Carbidopa-levodopa 25 mg-100 mg oral tablet |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
421 |
Carbidopa/l-dopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
422 |
Carbidopa/l-dopa/entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
423 |
Carbidopa/levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
424 |
Carbidopa/levodopa, immediate release |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
425 |
Carbidopa/levodopa/entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
426 |
Carbidopamonohydraat |
- |
- |
- |
- |
006 1件: 6 💬 |
427 |
Carbodopa levadopa |
- |
- |
- |
- |
006 1件: 6 💬 |
428 |
Carbodopa/levadopa |
- |
- |
- |
- |
006 1件: 6 💬 |
429 |
Carbon |
Activated charcoal |
1件: D03251 D03251 💬 |
- |
- |
006 9件: 6 , 46, 50, 51, 85, 86, 96, 97, 298 💬 |
430 |
Carnosine |
Carnosine |
- |
- |
- |
006 2件: 6 , 13 💬 |
431 |
Carnosine supplementation |
Carnosine |
- |
- |
- |
006 1件: 6 💬 |
432 |
Carvedilol |
Carvedilol |
2件: D00255 D00255, D03415 D03415 💬 |
ADRA1A 5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 💬 |
AMPK signaling pathway 12件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 5件: 6 , 57, 86, 113, 210 💬 |
433 |
Catapres ampoules |
- |
- |
- |
- |
006 1件: 6 💬 |
434 |
Catapressan |
- |
- |
- |
- |
006 1件: 6 💬 |
435 |
Cbd |
- |
- |
- |
- |
002 11件: 2 , 6 , 8 , 13, 46, 140, 144, 145, 156, 158, 206 💬 |
436 |
Cd |
- |
- |
- |
- |
006 6件: 6 , 46, 51, 96, 97, 265 💬 |
437 |
Cd-ld cr |
- |
- |
- |
- |
006 1件: 6 💬 |
438 |
Cd-ld ir |
- |
- |
- |
- |
006 1件: 6 💬 |
439 |
Cdnf |
- |
- |
- |
- |
006 1件: 6 💬 |
440 |
Ceftriaxone |
Ceftriaxone |
2件: D00924 D00924, D07659 D07659 💬 |
- |
- |
002 3件: 2 , 6 , 97 💬 |
441 |
Cep-1347 |
CEP-1347 |
- |
- |
- |
006 1件: 6 💬 |
442 |
Cep-1347 10mg |
CEP-1347 |
- |
- |
- |
006 1件: 6 💬 |
443 |
Cep-1347 50mg |
CEP-1347 |
- |
- |
- |
006 1件: 6 💬 |
444 |
Cep1347 |
- |
- |
- |
- |
006 1件: 6 💬 |
445 |
Cep1347 25mg |
- |
- |
- |
- |
006 1件: 6 💬 |
446 |
Cere-120 |
- |
- |
- |
- |
006 1件: 6 💬 |
447 |
Cere-120 (adeno-associated virus serotype 2 [aav2]-neurturin [ntn]) |
- |
- |
- |
- |
006 1件: 6 💬 |
448 |
Cere-120: adeno-associated virus delivery of neurturin |
- |
- |
- |
- |
006 1件: 6 💬 |
449 |
Cerebral dopamine neurotrophic factor |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
450 |
Ceretec |
- |
- |
- |
- |
006 1件: 6 💬 |
451 |
Ceretec (tm) estabilizado |
- |
- |
- |
- |
006 1件: 6 💬 |
452 |
Champix |
- |
- |
- |
- |
006 1件: 6 💬 |
453 |
Chloride |
Chloride ion |
- |
- |
- |
006 25件: 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 97, 127, 168, 171, 193, 227, 228, 271, 288, 296, 297, 299 💬 |
454 |
Chocolate |
Cocoa |
- |
- |
- |
006 1件: 6 💬 |
455 |
Cipralex |
- |
- |
- |
- |
006 1件: 6 💬 |
456 |
Circadin |
- |
- |
- |
- |
006 3件: 6 , 13, 90 💬 |
457 |
Circadin® |
- |
- |
- |
- |
006 1件: 6 💬 |
458 |
Citalopram |
Citalopram |
2件: D00822 D00822, D07704 D07704 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 6件: 6 , 8 , 13, 18, 46, 127 💬 |
459 |
Citalopram 20mg |
Citalopram |
2件: D00822 D00822, D07704 D07704 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 1件: 6 💬 |
460 |
Cjh1 (clr4001) |
- |
- |
- |
- |
006 1件: 6 💬 |
461 |
Clarithromycin |
Clarithromycin |
1件: D00276 D00276 💬 |
- |
- |
006 8件: 6 , 63, 84, 96, 97, 222, 228, 299 💬 |
462 |
Clarithromycin (not used as of 4/2020) |
Clarithromycin |
1件: D00276 D00276 💬 |
- |
- |
006 1件: 6 💬 |
463 |
Clarium 50 mg retardtabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
464 |
Clartihromycin, amoxicillin, and omeprazole |
Amoxicillin |
7件: D00229 D00229, D00455 D00455, D01207 D01207, D02925 D02925, D05259 D05259, D05261 D05261, D07452 D07452 💬 |
ATP4A 2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
006 1件: 6 💬 |
465 |
Cle |
- |
- |
- |
- |
006 1件: 6 💬 |
466 |
Clenbuterol |
Clenbuterol |
1件: D07713 D07713 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
001 4件: 1 , 2 , 6 , 256 💬 |
467 |
Clenbuterol hcl |
Clenbuterol |
1件: D07713 D07713 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
468 |
Clenbuterol hydrochloride |
Clenbuterol |
1件: D07713 D07713 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
469 |
Clonazepam |
Clonazepam |
1件: D00280 D00280 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 1件: 6 💬 |
470 |
Clonidine |
Clonidine |
2件: D00281 D00281, D00604 D00604 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 2件: 6 , 78 💬 |
471 |
Clonidine hydrochloride |
Clonidine |
2件: D00281 D00281, D00604 D00604 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 2件: 6 , 78 💬 |
472 |
Clozapine |
Clozapine |
1件: D00283 D00283 💬 |
ADRA2A 11件: ADRA2A, ADRA2B, ADRA2C, DRD4, HTR2A, HTR2C, HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 |
Calcium signaling pathway 8件: Calcium signaling pathway, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
473 |
Co |
- |
- |
- |
- |
006 5件: 6 , 13, 53, 70, 85 💬 |
474 |
Cocoa |
Cocoa |
- |
- |
- |
006 1件: 6 💬 |
475 |
Coenzyme q10 |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
002 12件: 2 , 5 , 6 , 8 , 10, 18, 46, 57, 113, 193, 214, 215 💬 |
476 |
Coenzyme q10 nanodispersion (nanoquinone) |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
006 1件: 6 💬 |
477 |
Coenzyme q10 with vitamin e |
Ubidecarenone |
2件: D01065 D01065, D02331 D02331 💬 |
- |
- |
006 1件: 6 💬 |
478 |
Cofactor |
- |
- |
- |
- |
006 3件: 6 , 265, 288 💬 |
479 |
Cogane |
- |
- |
- |
- |
006 1件: 6 💬 |
480 |
Cogane™ (pym50028) |
- |
- |
- |
- |
006 1件: 6 💬 |
481 |
Cohort 1:nilotinib oral capsules (150mg or 300mg) |
Nilotinib |
1件: D08953 D08953 💬 |
ABL1 4件: ABL1, KIT, PDGFRA, PDGFRB 💬 |
Acute myeloid leukemia 32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
006 1件: 6 💬 |
482 |
Cohort 2: nilotinib oral capsules (dose to be determined from cohort 1) |
Nilotinib |
1件: D08953 D08953 💬 |
ABL1 4件: ABL1, KIT, PDGFRA, PDGFRB 💬 |
Acute myeloid leukemia 32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
006 1件: 6 💬 |
483 |
Combination injection of epo and g-csf |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
006 1件: 6 💬 |
484 |
Combination product: l-dopa 140 mg |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
485 |
Combination product: l-dopa 35 mg |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
486 |
Combination product: l-dopa 70mg |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
487 |
Combination product: l-dopa 70mg/carbidopa 7mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
488 |
Combination product: nd0612 solution for sc infusion |
- |
- |
- |
- |
006 1件: 6 💬 |
489 |
Comparator: carbidopa |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
490 |
Comparator: levodopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
491 |
Comtan |
- |
- |
- |
- |
006 1件: 6 💬 |
492 |
Comtan 200* 60 cpr 200 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
493 |
Comtan® |
- |
- |
- |
- |
006 1件: 6 💬 |
494 |
Comtanâ® |
- |
- |
- |
- |
006 1件: 6 💬 |
495 |
Comtess |
- |
- |
- |
- |
006 1件: 6 💬 |
496 |
Comtess® |
- |
- |
- |
- |
006 1件: 6 💬 |
497 |
Continuous apomorphine infusion |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
498 |
Continuous intrajejunal infusion of levodopa-carbidopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
499 |
Continuous release dopamine agonists |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
500 |
Continuous subcutaneous lisuride infusion |
Lisuride |
2件: D01462 D01462, D08132 D08132 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
501 |
Control |
- |
- |
- |
- |
006 4件: 6 , 46, 168, 299 💬 |
502 |
Controlled-release levodopa / carbidopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
503 |
Coq10 |
- |
- |
- |
- |
005 3件: 5 , 6 , 8 💬 |
504 |
Cord blood therapy |
Umbilical Cord Blood Hematopoietic Stem Cells |
- |
- |
- |
002 2件: 2 , 6 💬 |
505 |
Cortef |
- |
- |
- |
- |
006 3件: 6 , 81, 83 💬 |
506 |
Cp |
- |
- |
- |
- |
006 6件: 6 , 46, 96, 97, 107, 271 💬 |
507 |
Creatine |
Creatine |
- |
- |
- |
001 12件: 1 , 2 , 5 , 6 , 8 , 13, 46, 49, 50, 113, 156, 201 💬 |
508 |
Cst-103 |
- |
- |
- |
- |
006 1件: 6 💬 |
509 |
Cst-139 |
- |
- |
- |
- |
006 1件: 6 💬 |
510 |
Cu(ii)atsm |
- |
- |
- |
- |
002 2件: 2 , 6 💬 |
511 |
Cvd00118-e |
- |
- |
- |
- |
006 1件: 6 💬 |
512 |
Cvl-751 |
- |
- |
- |
- |
006 1件: 6 💬 |
513 |
Cvn424 high dose |
- |
- |
- |
- |
006 1件: 6 💬 |
514 |
Cvn424 low dose |
- |
- |
- |
- |
006 1件: 6 💬 |
515 |
Cvt-301 |
- |
- |
- |
- |
006 1件: 6 💬 |
516 |
Cvt-301 (dose level 1) |
- |
- |
- |
- |
006 1件: 6 💬 |
517 |
Cvt-301 (dose level 2) |
- |
- |
- |
- |
006 1件: 6 💬 |
518 |
Cvt-301 35mg |
- |
- |
- |
- |
006 1件: 6 💬 |
519 |
Cvt-301 50mg |
- |
- |
- |
- |
006 1件: 6 💬 |
520 |
Cvt-301 high dose |
- |
- |
- |
- |
006 1件: 6 💬 |
521 |
Cvt-301 low dose |
- |
- |
- |
- |
006 1件: 6 💬 |
522 |
Cvt-301, lip |
- |
- |
- |
- |
006 1件: 6 💬 |
523 |
Cvxl-0107 |
- |
- |
- |
- |
006 1件: 6 💬 |
524 |
Cx-8998 |
- |
- |
- |
- |
006 1件: 6 💬 |
525 |
Cyberknife |
- |
- |
- |
- |
006 1件: 6 💬 |
526 |
Cymbalta |
- |
- |
- |
- |
006 3件: 6 , 13, 49 💬 |
527 |
Cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
006 11件: 6 , 13, 19, 34, 84, 85, 88, 90, 254, 296, 310 💬 |
528 |
Cystoscopic injection of botox into the urinary bladder |
- |
- |
- |
- |
006 1件: 6 💬 |
529 |
D-serine |
D-Serine |
1件: D00016 D00016 💬 |
- |
- |
006 1件: 6 💬 |
530 |
D-serine (~2g/day) |
D-Serine |
1件: D00016 D00016 💬 |
- |
- |
006 1件: 6 💬 |
531 |
Da-9701 |
- |
- |
- |
- |
006 1件: 6 💬 |
532 |
Da-9805 45mg |
- |
- |
- |
- |
006 1件: 6 💬 |
533 |
Da-9805 90mg |
- |
- |
- |
- |
006 1件: 6 💬 |
534 |
Daaoi-p |
- |
- |
- |
- |
006 1件: 6 💬 |
535 |
Dacepton 5 mg/ml |
- |
- |
- |
- |
006 1件: 6 💬 |
536 |
Dacepton 5 mg/ml infuusioneste, liuos |
- |
- |
- |
- |
006 1件: 6 💬 |
537 |
Daily ingestion of lactobacillus plantarum ps128 |
Lactobacillus plantarum |
- |
- |
- |
006 1件: 6 💬 |
538 |
Darifenacin |
Darifenacin |
2件: D01699 D01699, D03654 D03654 💬 |
CHRM3 1件: CHRM3 💬 |
Alzheimer disease 11件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
006 2件: 6 , 13 💬 |
539 |
Dark chocolate (85% cocoa) |
Cocoa |
- |
- |
- |
006 1件: 6 💬 |
540 |
Datscan |
- |
- |
- |
- |
002 4件: 2 , 5 , 6 , 17 💬 |
541 |
Datscan 74 mbq/ml solution for injection |
- |
- |
- |
- |
006 1件: 6 💬 |
542 |
Datscan™ |
- |
- |
- |
- |
006 1件: 6 💬 |
543 |
Datscan™ ioflupane (123i) injection |
- |
- |
- |
- |
005 3件: 5 , 6 , 17 💬 |
544 |
Dc158am |
- |
- |
- |
- |
006 1件: 6 💬 |
545 |
Dci |
- |
- |
- |
- |
006 2件: 6 , 299 💬 |
546 |
Dcs |
- |
- |
- |
- |
006 1件: 6 💬 |
547 |
Deanol |
Deanol |
1件: D07777 D07777 💬 |
- |
- |
006 1件: 6 💬 |
548 |
Deanol pyroglutamate |
Deanol |
1件: D07777 D07777 💬 |
- |
- |
006 1件: 6 💬 |
549 |
Debrumyl |
- |
- |
- |
- |
006 1件: 6 💬 |
550 |
Deferiprone |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
002 6件: 2 , 6 , 18, 120, 122, 233 💬 |
551 |
Deferiprone (ferriprox) |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
552 |
Deferiprone 20mg |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
553 |
Deferiprone 30mg |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
554 |
Deferiprone 600 mg delayed release tablet |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
555 |
Deferiprone dr |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
556 |
Desipramine |
Desipramine |
2件: D00812 D00812, D07791 D07791 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 4件: 6 , 17, 120, 156 💬 |
557 |
Desipramine (dmi) |
Desipramine |
2件: D00812 D00812, D07791 D07791 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6 , 17 💬 |
558 |
Desmopressin |
Desmopressin |
2件: D00291 D00291, D02235 D02235 💬 |
AVPR2 2件: AVPR2, F8 💬 |
Complement and coagulation cascades 4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
006 5件: 6 , 64, 72, 225, 288 💬 |
559 |
Desmopressin acetat |
Desmopressin |
2件: D00291 D00291, D02235 D02235 💬 |
AVPR2 2件: AVPR2, F8 💬 |
Complement and coagulation cascades 4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
006 1件: 6 💬 |
560 |
Desmotabs |
- |
- |
- |
- |
006 1件: 6 💬 |
561 |
Desmotabs® 0,2 mg tabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
562 |
Desmotabs® 0,2mg tabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
563 |
Determination of drug effects through amantadine cessation |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
564 |
Device: abdominal compression |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
565 |
Device: actimyo recording |
- |
- |
- |
- |
006 1件: 6 💬 |
566 |
Device: active tdcs |
- |
- |
- |
- |
006 1件: 6 💬 |
567 |
Device: active tpcs |
- |
- |
- |
- |
006 1件: 6 💬 |
568 |
Device: adaptor: hakko adaptor |
- |
- |
- |
- |
006 1件: 6 💬 |
569 |
Device: aha exergame system |
- |
- |
- |
- |
006 1件: 6 💬 |
570 |
Device: b-stn dbs |
- |
- |
- |
- |
006 1件: 6 💬 |
571 |
Device: balance training |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
572 |
Device: balance training with nintendo wii fit |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
573 |
Device: cadd-legacy ambulatory infusion pump |
- |
- |
- |
- |
006 1件: 6 💬 |
574 |
Device: cadd-legacy® 1400 ambulatory infusion pump |
- |
- |
- |
- |
006 1件: 6 💬 |
575 |
Device: carbon fiber ankle foot orthosis (afo) |
Activated charcoal |
1件: D03251 D03251 💬 |
- |
- |
006 1件: 6 💬 |
576 |
Device: clonidine (catapressan) |
Clonidine |
2件: D00281 D00281, D00604 D00604 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
577 |
Device: deep brain stimulation |
- |
- |
- |
- |
005 5件: 5 , 6 , 7 , 8 , 17 💬 |
578 |
Device: functional magnetic resonance imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
579 |
Device: infusion pump: cadd-legacy® 1400 pump |
- |
- |
- |
- |
006 1件: 6 💬 |
580 |
Device: inspiratory muscle training |
- |
- |
- |
- |
006 1件: 6 💬 |
581 |
Device: j-tube |
- |
- |
- |
- |
006 1件: 6 💬 |
582 |
Device: jejunal extension tube |
- |
- |
- |
- |
006 1件: 6 💬 |
583 |
Device: jejunal extension tube (j-tube) |
- |
- |
- |
- |
006 1件: 6 💬 |
584 |
Device: kinetra and soletra (neurostimulator, medtronic) |
- |
- |
- |
- |
006 1件: 6 💬 |
585 |
Device: light box ( litebook company) |
- |
- |
- |
- |
006 1件: 6 💬 |
586 |
Device: light box (litebook company) |
- |
- |
- |
- |
006 1件: 6 💬 |
587 |
Device: magnetic resonance imaging |
- |
- |
- |
- |
006 5件: 6 , 13, 22, 34, 299 💬 |
588 |
Device: massage with a spiky ball |
- |
- |
- |
- |
006 1件: 6 💬 |
589 |
Device: ms band 2 |
- |
- |
- |
- |
006 1件: 6 💬 |
590 |
Device: nebulizer |
- |
- |
- |
- |
006 1件: 6 💬 |
591 |
Device: nj-tube: silicon ed tube |
Silicon |
- |
- |
- |
006 1件: 6 💬 |
592 |
Device: oct - tce |
- |
- |
- |
- |
006 1件: 6 💬 |
593 |
Device: peg tube |
- |
- |
- |
- |
006 1件: 6 💬 |
594 |
Device: percutaneous endoscopic gastrostomy tube |
- |
- |
- |
- |
006 1件: 6 💬 |
595 |
Device: percutaneous endoscopic gastrostomy tube (peg tube) |
- |
- |
- |
- |
006 1件: 6 💬 |
596 |
Device: renishaw drug delivery system |
- |
- |
- |
- |
006 1件: 6 💬 |
597 |
Device: resistive respiratory loads |
- |
- |
- |
- |
006 1件: 6 💬 |
598 |
Device: sham compression |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
599 |
Device: sham tdcs |
- |
- |
- |
- |
006 1件: 6 💬 |
600 |
Device: sham tpcs |
- |
- |
- |
- |
006 1件: 6 💬 |
601 |
Device: spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
602 |
Device: spoton balance glasses |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
603 |
Device: stimulator off |
- |
- |
- |
- |
006 1件: 6 💬 |
604 |
Device: stimulator on |
- |
- |
- |
- |
006 1件: 6 💬 |
605 |
Dexdor |
- |
- |
- |
- |
002 4件: 2 , 4 , 6 , 70 💬 |
606 |
Dexmedetomidina |
Dexmedetomidine |
2件: D00514 D00514, D01205 D01205 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
607 |
Dexmedetomidine |
Dexmedetomidine |
2件: D00514 D00514, D01205 D01205 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
002 12件: 2 , 4 , 6 , 21, 34, 46, 70, 113, 212, 215, 226, 280 💬 |
608 |
Dexmedetomidine hydrochloride infusion |
Dexmedetomidine |
2件: D00514 D00514, D01205 D01205 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
609 |
Dextromethorphan |
Dextromethorphan |
3件: D00848 D00848, D03742 D03742, D03744 D03744 💬 |
GRIN1 6件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SIGMAR1 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
002 11件: 2 , 6 , 8 , 13, 21, 46, 78, 85, 96, 97, 156 💬 |
610 |
Dha |
- |
- |
- |
- |
006 8件: 6 , 46, 48, 49, 94, 113, 299, 301 💬 |
611 |
Diagnostic test: [18f]-ro6958948 |
- |
- |
- |
- |
005 5件: 5 , 6 , 7 , 17, 127 💬 |
612 |
Diagnostic test: auto-assessment manikins (sam) |
- |
- |
- |
- |
006 1件: 6 💬 |
613 |
Diagnostic test: barcelona test (bt) |
- |
- |
- |
- |
006 1件: 6 💬 |
614 |
Diagnostic test: beam test to predict falls |
Tricyclazole |
- |
- |
- |
006 1件: 6 💬 |
615 |
Diagnostic test: beck depression inventory-ii (bdi-ii) |
- |
- |
- |
- |
006 1件: 6 💬 |
616 |
Diagnostic test: elecsys (roche) abeta42, ttau and ptau |
- |
- |
- |
- |
005 5件: 5 , 6 , 7 , 17, 127 💬 |
617 |
Diagnostic test: flutemetamol f18 injection |
Flutemetamol |
1件: D10231 D10231 💬 |
- |
- |
005 5件: 5 , 6 , 7 , 17, 127 💬 |
618 |
Diagnostic test: frontal assessment battery (fab) |
- |
- |
- |
- |
006 1件: 6 💬 |
619 |
Diagnostic test: global deterioration scale (gds) |
- |
- |
- |
- |
006 1件: 6 💬 |
620 |
Diagnostic test: lumipulse (fujirebio) abeta42, ttau and ptau |
- |
- |
- |
- |
005 5件: 5 , 6 , 7 , 17, 127 💬 |
621 |
Diagnostic test: measurement of serum level of anti-dementia drug |
- |
- |
- |
- |
006 1件: 6 💬 |
622 |
Diagnostic test: memory alteration test (m@t) |
- |
- |
- |
- |
006 1件: 6 💬 |
623 |
Diagnostic test: mini cognitive examination (mce) |
- |
- |
- |
- |
006 1件: 6 💬 |
624 |
Diagnostic test: neuropsychological assessment |
- |
- |
- |
- |
006 2件: 6 , 127 💬 |
625 |
Diagnostic test: positive and negative affect scale (panas) |
- |
- |
- |
- |
006 1件: 6 💬 |
626 |
Diagnostic test: respiratory muscle strength |
- |
- |
- |
- |
006 1件: 6 💬 |
627 |
Diagnostic test: rey-osterrieth complex figure test (rocft) |
- |
- |
- |
- |
006 1件: 6 💬 |
628 |
Diagnostic test: spanish-complutense verbal learning test (tavec) |
- |
- |
- |
- |
006 1件: 6 💬 |
629 |
Diagnostic test: supplementary neuropsychological assessment - parkinson's disease |
- |
- |
- |
- |
006 2件: 6 , 127 💬 |
630 |
Different diets |
- |
- |
- |
- |
006 1件: 6 💬 |
631 |
Dihydroergotoxine mesylate |
Ergoloid mesylate |
1件: D02268 D02268 💬 |
ADRA1A 6件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C 💬 |
AMPK signaling pathway 7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
632 |
Dipivefrin |
Dipivefrin |
1件: D02349 D02349 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
633 |
Dipivefrine |
Dipivefrin |
1件: D02349 D02349 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
634 |
Dipraglurant |
Dipraglurant |
- |
- |
- |
006 1件: 6 💬 |
635 |
Ditropan elixir |
- |
- |
- |
- |
006 1件: 6 💬 |
636 |
Dm |
- |
- |
- |
- |
006 2件: 6 , 8 💬 |
637 |
Dm-1992 |
- |
- |
- |
- |
006 1件: 6 💬 |
638 |
Dmi |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
639 |
Dnl151 |
- |
- |
- |
- |
006 1件: 6 💬 |
640 |
Dnl201 |
- |
- |
- |
- |
006 1件: 6 💬 |
641 |
Dns-7801 (high dose) |
- |
- |
- |
- |
006 1件: 6 💬 |
642 |
Dns-7801 (low-dose) |
- |
- |
- |
- |
006 1件: 6 💬 |
643 |
Docosahexaenoic acid |
Doconexent |
- |
- |
- |
006 7件: 6 , 49, 90, 94, 240, 299, 301 💬 |
644 |
Docosahexaenoic acid (dha) |
Doconexent |
- |
- |
- |
006 3件: 6 , 94, 299 💬 |
645 |
Domperidone |
Domperidone |
2件: D01745 D01745, D07868 D07868 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 5件: 6 , 13, 17, 51, 230 💬 |
646 |
Domperidone (drug) |
Domperidone |
2件: D01745 D01745, D07868 D07868 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
647 |
Dompéridone |
- |
- |
- |
- |
006 1件: 6 💬 |
648 |
Donepezil |
Donepezil |
2件: D00670 D00670, D07869 D07869 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
005 9件: 5 , 6 , 13, 46, 78, 124, 127, 156, 206 💬 |
649 |
Donepezil hydrochloride |
Donepezil |
2件: D00670 D00670, D07869 D07869 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 3件: 6 , 124, 156 💬 |
650 |
Donepezil sandoz |
Donepezil |
2件: D00670 D00670, D07869 D07869 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
651 |
Dopamine |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 3件: 6 , 7 , 74 💬 |
652 |
Dopamine agent |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
653 |
Dopamine agonists (pramipexole, ropirinole) |
Dopamine |
4件: D00559 D00559, D00633 D00633, D05575 D05575, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
654 |
Dopaminergic agonist + apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
655 |
Dopaminergic agonists |
- |
- |
- |
- |
006 1件: 6 💬 |
656 |
Dops |
Droxidopa |
1件: D01277 D01277 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 2件: 6 , 17 💬 |
657 |
Doxepin |
Doxepin |
2件: D00814 D00814, D07875 D07875 💬 |
HRH1 3件: HRH1, SLC6A2, SLC6A4 💬 |
Calcium signaling pathway 5件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
006 1件: 6 💬 |
658 |
Doxepin and zopiclone |
Doxepin |
3件: D00814 D00814, D01372 D01372, D07875 D07875 💬 |
GABRA1 19件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, SLC6A2, SLC6A4 💬 |
Calcium signaling pathway 10件: Calcium signaling pathway, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction |
006 1件: 6 💬 |
659 |
Dpa |
- |
- |
- |
- |
002 4件: 2 , 6 , 13, 85 💬 |
660 |
Dpa-714-pet/mri |
- |
- |
- |
- |
006 1件: 6 💬 |
661 |
Droxidopa |
Droxidopa |
1件: D01277 D01277 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
005 3件: 5 , 6 , 17 💬 |
662 |
Droxidopa 100 mg [northera] |
Droxidopa |
1件: D01277 D01277 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
663 |
Duloxetine |
Duloxetine |
2件: D01179 D01179, D07880 D07880 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6 , 13 💬 |
664 |
Duloxetine hydrochloride |
Duloxetine |
2件: D01179 D01179, D07880 D07880 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 1件: 6 💬 |
665 |
Duodopa |
- |
- |
- |
- |
006 1件: 6 💬 |
666 |
Duodopa gel intestinale |
- |
- |
- |
- |
006 1件: 6 💬 |
667 |
Duodopa intestinal gel |
- |
- |
- |
- |
006 1件: 6 💬 |
668 |
Duodopa intestinalgel |
- |
- |
- |
- |
006 1件: 6 💬 |
669 |
Duodopa ld/cd 20/5 mg/ml |
- |
- |
- |
- |
006 1件: 6 💬 |
670 |
Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel |
- |
- |
- |
- |
006 1件: 6 💬 |
671 |
Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
672 |
Duodopa®intestinal gel |
- |
- |
- |
- |
006 1件: 6 💬 |
673 |
Dynacirc cr (isradipine) |
Isradipine |
1件: D00349 D00349 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
674 |
E2007 |
- |
- |
- |
- |
006 2件: 6 , 144 💬 |
675 |
Ebixa |
- |
- |
- |
- |
002 3件: 2 , 6 , 13 💬 |
676 |
Ebixa® |
- |
- |
- |
- |
006 1件: 6 💬 |
677 |
Egcg |
Epigallocatechin gallate |
- |
- |
- |
006 9件: 6 , 8 , 13, 17, 28, 85, 113, 206, 299 💬 |
678 |
Elc200 |
- |
- |
- |
- |
006 1件: 6 💬 |
679 |
Eliprodil |
Eliprodil |
- |
- |
- |
006 1件: 6 💬 |
680 |
Elobixibat |
Elobixibat |
1件: D10796 D10796 💬 |
SLC10A2 1件: SLC10A2 💬 |
Bile secretion 1件: Bile secretion |
006 1件: 6 💬 |
681 |
Eltoprazine |
Eltoprazine |
- |
- |
- |
006 1件: 6 💬 |
682 |
Eltoprazine hcl |
Eltoprazine |
- |
- |
- |
006 1件: 6 💬 |
683 |
Eltoprazine hydrochloride |
Eltoprazine |
- |
- |
- |
006 1件: 6 💬 |
684 |
Emd 128130 |
- |
- |
- |
- |
006 2件: 6 , 156 💬 |
685 |
Emd128130 |
- |
- |
- |
- |
006 1件: 6 💬 |
686 |
En |
- |
- |
- |
- |
006 3件: 6 , 46, 97 💬 |
687 |
Ena713 |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
688 |
Ena713b |
- |
- |
- |
- |
006 1件: 6 💬 |
689 |
Ent-01 |
- |
- |
- |
- |
006 1件: 6 💬 |
690 |
Entacapon |
- |
- |
- |
- |
006 1件: 6 💬 |
691 |
Entacapona |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
692 |
Entacapone |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 2件: 6 , 17 💬 |
693 |
Entacapone 400mg oral dose |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 2件: 6 , 17 💬 |
694 |
Entacapone and carbidopa |
Carbidopa |
2件: D00558 D00558, D00781 D00781 💬 |
COMT 2件: COMT, DDC 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
695 |
Entacapone inn |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
696 |
Entecapone |
- |
- |
- |
- |
006 1件: 6 💬 |
697 |
Epi-589 |
EPI-589 |
- |
- |
- |
002 2件: 2 , 6 💬 |
698 |
Epi-743 200mg |
- |
- |
- |
- |
006 1件: 6 💬 |
699 |
Epi-743 400mg |
- |
- |
- |
- |
006 1件: 6 💬 |
700 |
Equal |
- |
- |
- |
- |
006 5件: 6 , 13, 67, 86, 230 💬 |
701 |
Er cd-ld |
- |
- |
- |
- |
006 1件: 6 💬 |
702 |
Er tablet 100 mg azd3241 |
- |
- |
- |
- |
006 1件: 6 💬 |
703 |
Er tablet 25 mg azd3241 |
- |
- |
- |
- |
006 1件: 6 💬 |
704 |
Eradication of helcobacter pylori |
- |
- |
- |
- |
006 1件: 6 💬 |
705 |
Eradication therapy for h.pylori infection |
- |
- |
- |
- |
006 1件: 6 💬 |
706 |
Eradication therapy for helicobacter pylori |
- |
- |
- |
- |
006 1件: 6 💬 |
707 |
Erythromycin |
Erythromycin |
9件: D00140 D00140, D00851 D00851, D01361 D01361, D02009 D02009, D02184 D02184, D02523 D02523, D02524 D02524, D02525 D02525, D04054 D04054 💬 |
- |
- |
006 5件: 6 , 36, 164, 228, 291 💬 |
708 |
Erythropoietin |
Erythropoietin |
1件: D03231 D03231 💬 |
EPOR 1件: EPOR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 9件: 2 , 6 , 13, 18, 22, 47, 70, 95, 96 💬 |
709 |
Erythropoietin human recombinant (eporh) |
Erythropoietin |
1件: D03231 D03231 💬 |
EPOR 1件: EPOR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
006 1件: 6 💬 |
710 |
Escitalopram |
Escitalopram |
3件: D02567 D02567, D07704 D07704, D07913 D07913 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
002 3件: 2 , 6 , 13 💬 |
711 |
Escitalopram oxalate |
Escitalopram |
3件: D02567 D02567, D07704 D07704, D07913 D07913 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 1件: 6 💬 |
712 |
Eszopiclone |
Eszopiclone |
1件: D02624 D02624 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 3件: 6 , 13, 46 💬 |
713 |
Ethnodyne visio |
- |
- |
- |
- |
006 1件: 6 💬 |
714 |
Ethylmethylcarbamic acid 3-[(1s)-1-(dimethylamino)ethyl]phenyl ester (**see other 2 names below) |
- |
- |
- |
- |
006 1件: 6 💬 |
715 |
Exametazime |
Exametazime |
1件: D01109 D01109 💬 |
- |
- |
006 1件: 6 💬 |
716 |
Exelon |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
717 |
Exelon 4.6 mg/24 h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
718 |
Exelon 9.5 mg/24 h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
719 |
Exelon patch |
- |
- |
- |
- |
006 1件: 6 💬 |
720 |
Exelon patch (rivastigmine transdermal system) |
Rivastigmine |
2件: D02558 D02558, D03822 D03822 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
721 |
Exelon path transdermal |
- |
- |
- |
- |
006 1件: 6 💬 |
722 |
Exelon ® |
- |
- |
- |
- |
006 1件: 6 💬 |
723 |
Exenatide |
Exenatide |
1件: D04121 D04121 💬 |
GLP1R 1件: GLP1R 💬 |
Insulin secretion 3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
006 4件: 6 , 17, 193, 233 💬 |
724 |
Exenatide 10 micrograms |
Exenatide |
1件: D04121 D04121 💬 |
GLP1R 1件: GLP1R 💬 |
Insulin secretion 3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
006 1件: 6 💬 |
725 |
Exenatide 5 micrograms |
Exenatide |
1件: D04121 D04121 💬 |
GLP1R 1件: GLP1R 💬 |
Insulin secretion 3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
006 1件: 6 💬 |
726 |
Exenatide extended release 2mg (bydureon) |
Exenatide |
1件: D04121 D04121 💬 |
GLP1R 1件: GLP1R 💬 |
Insulin secretion 3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
006 1件: 6 💬 |
727 |
F-18 fpcit |
- |
- |
- |
- |
006 1件: 6 💬 |
728 |
Famotidine |
Famotidine |
1件: D00318 D00318 💬 |
HRH2 1件: HRH2 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
006 4件: 6 , 46, 86, 98 💬 |
729 |
Fb-101 |
- |
- |
- |
- |
006 1件: 6 💬 |
730 |
Febuxostat |
Febuxostat |
1件: D01206 D01206 💬 |
XDH 1件: XDH 💬 |
Caffeine metabolism 5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
002 3件: 2 , 6 , 13 💬 |
731 |
Ferriprox |
- |
- |
- |
- |
006 2件: 6 , 120 💬 |
732 |
Ferriprox 500 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
733 |
Ferrprox (deferiprone) |
Deferiprone |
1件: D07416 D07416 💬 |
- |
- |
006 1件: 6 💬 |
734 |
Fesoterodine |
Fesoterodine |
1件: D07226 D07226 💬 |
CHRM2 2件: CHRM2, CHRM3 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
735 |
Fetal porcine cells, neurocell-pd |
- |
- |
- |
- |
006 1件: 6 💬 |
736 |
Filgrastim |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 27件: 2 , 6 , 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 |
737 |
Finamine tablets |
- |
- |
- |
- |
006 1件: 6 💬 |
738 |
Finasteride |
Finasteride |
1件: D00321 D00321 💬 |
SRD5A2 1件: SRD5A2 💬 |
Prostate cancer 2件: Prostate cancer, Steroid hormone biosynthesis |
006 1件: 6 💬 |
739 |
Fipamezole |
Fipamezole |
- |
- |
- |
006 2件: 6 , 17 💬 |
740 |
Fipamezole hydrochloride |
Fipamezole |
- |
- |
- |
006 2件: 6 , 17 💬 |
741 |
Fipamezole hydrochloride 30 mg oral disintegrating tablets |
Fipamezole |
- |
- |
- |
006 2件: 6 , 17 💬 |
742 |
Fipamezole hydrochloride 60 mg oral disintegrating tablets |
Fipamezole |
- |
- |
- |
006 2件: 6 , 17 💬 |
743 |
Fipamezole hydrochloride 90 mg oral disintegrating tablets |
Fipamezole |
- |
- |
- |
006 2件: 6 , 17 💬 |
744 |
Fipamezole odt |
Fipamezole |
- |
- |
- |
006 1件: 6 💬 |
745 |
Fipamezole odt cohort 2 |
Fipamezole |
- |
- |
- |
006 1件: 6 💬 |
746 |
Flecainide |
Flecainide |
2件: D00638 D00638, D07962 D07962 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 1件: 6 💬 |
747 |
Flecainide acetate |
Acetate |
2件: D00638 D00638, D07962 D07962 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 1件: 6 💬 |
748 |
Flecainidum |
Flecainide |
2件: D00638 D00638, D07962 D07962 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 1件: 6 💬 |
749 |
Florbetaben (18f) |
- |
- |
- |
- |
006 1件: 6 💬 |
750 |
Florbetapir f 18 |
- |
- |
- |
- |
006 1件: 6 💬 |
751 |
Fludrocortisone |
Fludrocortisone |
2件: D00986 D00986, D07967 D07967 💬 |
NR3C2 1件: NR3C2 💬 |
Aldosterone-regulated sodium reabsorption 1件: Aldosterone-regulated sodium reabsorption |
006 3件: 6 , 17, 81 💬 |
752 |
Flumazenil |
Flumazenil |
1件: D00697 D00697 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 5件: 6 , 13, 17, 18, 206 💬 |
753 |
Flutemetamol |
Flutemetamol |
- |
- |
- |
005 5件: 5 , 6 , 7 , 17, 127 💬 |
754 |
Flutemetamol f18 |
Flutemetamol |
1件: D10231 D10231 💬 |
- |
- |
005 5件: 5 , 6 , 7 , 17, 127 💬 |
755 |
Folic acid |
Folic acid |
1件: D00070 D00070 💬 |
- |
- |
006 4件: 6 , 46, 49, 84 💬 |
756 |
Folic acid, vitamin b6, vitamin b12 |
Cyanocobalamin |
7件: D00070 D00070, D00166 D00166, D02179 D02179, D03615 D03615, D03616 D03616, D03617 D03617, D08454 D08454 💬 |
- |
- |
006 1件: 6 💬 |
757 |
Foliglurax |
Foliglurax |
- |
- |
- |
006 1件: 6 💬 |
758 |
Foliglurax 10 mg (treatment a) |
Foliglurax |
- |
- |
- |
006 1件: 6 💬 |
759 |
Foliglurax 30 mg (treatment b) |
Foliglurax |
- |
- |
- |
006 1件: 6 💬 |
760 |
Foscarbidopa |
Foscarbidopa |
- |
- |
- |
006 1件: 6 💬 |
761 |
Foscarbidopa and foslevodopa |
Foscarbidopa |
- |
- |
- |
006 1件: 6 💬 |
762 |
Foslevodopa |
- |
- |
- |
- |
006 1件: 6 💬 |
763 |
Fpf1100nw |
- |
- |
- |
- |
006 1件: 6 💬 |
764 |
Fpfs-1169 |
- |
- |
- |
- |
006 1件: 6 💬 |
765 |
G-csf |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 16件: 2 , 6 , 11, 13, 16, 47, 49, 51, 60, 62, 65, 85, 96, 284, 285, 331 💬 |
766 |
Gabapentin |
Gabapentin |
1件: D00332 D00332 💬 |
CACNA2D1 5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 |
Adrenergic signaling in cardiomyocytes 9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
006 5件: 6 , 13, 19, 70, 298 💬 |
767 |
Gabapentina |
Gabapentin |
1件: D00332 D00332 💬 |
CACNA2D1 5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 |
Adrenergic signaling in cardiomyocytes 9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
006 1件: 6 💬 |
768 |
Gabapentina kern pharma |
Gabapentin |
1件: D00332 D00332 💬 |
CACNA2D1 5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 |
Adrenergic signaling in cardiomyocytes 9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
006 1件: 6 💬 |
769 |
Galantamine |
Galantamine |
2件: D02173 D02173, D04292 D04292 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 2件: 6 , 127 💬 |
770 |
Ganoderma |
- |
- |
- |
- |
006 1件: 6 💬 |
771 |
Genetic: optional pharmacogenetic assessment |
- |
- |
- |
- |
006 1件: 6 💬 |
772 |
Genz-682452 |
Venglustat |
1件: D11633 D11633 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
006 3件: 6 , 19, 67 💬 |
773 |
Genz-682452-au |
Venglustat |
1件: D11633 D11633 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
006 3件: 6 , 19, 67 💬 |
774 |
Ghrelin |
Lenomorelin |
- |
- |
- |
006 3件: 6 , 78, 299 💬 |
775 |
Ginkgo |
Ginkgo biloba |
- |
- |
- |
006 4件: 6 , 13, 18, 90 💬 |
776 |
Glial cell line-derived neurotrophic factor |
- |
- |
- |
- |
006 1件: 6 💬 |
777 |
Glial cell line-derived neurotrophic factor (gdnf) |
- |
- |
- |
- |
006 1件: 6 💬 |
778 |
Glucose |
Dextrose, unspecified form |
- |
- |
- |
002 15件: 2 , 6 , 13, 49, 50, 65, 75, 86, 88, 96, 160, 195, 254, 257, 299 💬 |
779 |
Glutathione |
Glutathione |
2件: D00014 D00014, D00031 D00031 💬 |
- |
- |
006 2件: 6 , 299 💬 |
780 |
Glycerol |
Glycerin |
1件: D00028 D00028 💬 |
- |
- |
006 5件: 6 , 13, 79, 316, 317 💬 |
781 |
Glycerol phenylbutyrate |
Glycerin |
3件: D00028 D00028, D05868 D05868, D10127 D10127 💬 |
- |
- |
006 1件: 6 💬 |
782 |
Glycopyrrolate |
- |
- |
- |
- |
006 2件: 6 , 34 💬 |
783 |
Gm1 ganglioside |
- |
- |
- |
- |
006 1件: 6 💬 |
784 |
Gm608 |
- |
- |
- |
- |
006 1件: 6 💬 |
785 |
Gocovri |
- |
- |
- |
- |
006 1件: 6 💬 |
786 |
Gold |
Gold |
- |
- |
- |
002 38件: 2 , 5 , 6 , 13, 17, 34, 46, 49, 50, 53, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 158, 162, 171, 218, 222, 224, 227, 230, 271, 291, 294, 296, 298, 299, 310, 318 💬 |
787 |
Gold nanocrystals |
Gold |
- |
- |
- |
002 3件: 2 , 6 , 13 💬 |
788 |
Gpi 1485 |
- |
- |
- |
- |
006 1件: 6 💬 |
789 |
Grapefruit |
Grapefruit |
- |
- |
- |
006 5件: 6 , 46, 50, 83, 97 💬 |
790 |
Green tea |
Green tea leaf |
1件: D06903 D06903 💬 |
- |
- |
006 5件: 6 , 17, 28, 46, 96 💬 |
791 |
Green tea polyphenols (egcg/ecg) |
Epigallocatechin gallate |
1件: D06903 D06903 💬 |
- |
- |
006 1件: 6 💬 |
792 |
Grf6021 |
- |
- |
- |
- |
006 1件: 6 💬 |
793 |
Group ad anti-pd + antidepressant |
- |
- |
- |
- |
006 1件: 6 💬 |
794 |
Group r rasagiline |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
795 |
Group r+ad rasagiline + antidepressant |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
796 |
Gsh |
- |
- |
- |
- |
006 2件: 6 , 299 💬 |
797 |
Gsk962040 |
- |
- |
- |
- |
006 1件: 6 💬 |
798 |
Gsk962040 (25 mg tablet) |
- |
- |
- |
- |
006 1件: 6 💬 |
799 |
Guar gum |
Guar gum |
1件: D04403 D04403 💬 |
- |
- |
006 1件: 6 💬 |
800 |
Gz/sar402671 |
- |
- |
- |
- |
006 2件: 6 , 19 💬 |
801 |
Hb-admscs |
Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins |
- |
- |
- |
002 3件: 2 , 6 , 46 💬 |
802 |
Hec122505msoh |
- |
- |
- |
- |
006 1件: 6 💬 |
803 |
Helicobacter pylori eradication therapy |
- |
- |
- |
- |
006 1件: 6 💬 |
804 |
Heptaminol |
Heptaminol |
1件: D07158 D07158 💬 |
- |
- |
006 1件: 6 💬 |
805 |
Heptaminol hydrochloride |
Heptaminol |
1件: D07158 D07158 💬 |
- |
- |
006 1件: 6 💬 |
806 |
Herbal medicinal mixture (roucongrong, heshouwu etc.) |
Reynoutria multiflora root |
- |
- |
- |
006 1件: 6 💬 |
807 |
Hericium erinaceus mycelium |
- |
- |
- |
- |
006 1件: 6 💬 |
808 |
Heshouwu |
Reynoutria multiflora root |
- |
- |
- |
006 1件: 6 💬 |
809 |
Hf0220 |
- |
- |
- |
- |
006 1件: 6 💬 |
810 |
High dose affitope® pd03a + adjuvant |
- |
- |
- |
- |
006 1件: 6 💬 |
811 |
High dose anavex2-73 |
- |
- |
- |
- |
006 1件: 6 💬 |
812 |
High protein. t-diet plus range |
- |
- |
- |
- |
006 1件: 6 💬 |
813 |
Hp-3000 (ropinirole hydrochloride patch) |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
814 |
Hp-3000 placebo |
- |
- |
- |
- |
006 1件: 6 💬 |
815 |
Hp-3000(ropinirole hydrochloride patch) |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
816 |
Human amniotic epithelial stem cells |
- |
- |
- |
- |
006 1件: 6 💬 |
817 |
Human neural stem cell |
- |
- |
- |
- |
006 1件: 6 💬 |
818 |
Human stem cells |
- |
- |
- |
- |
006 1件: 6 💬 |
819 |
Hydrocortisone |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 9件: 6 , 46, 53, 75, 78, 81, 83, 97, 299 💬 |
820 |
Hydrocortisone cream |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
821 |
Hydrocortisone cream 1% |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
822 |
Hydrocortisone cream 10mg/g fna fagron |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
823 |
Hydrogen |
Hydrogen |
- |
- |
- |
005 7件: 5 , 6 , 13, 17, 83, 97, 226 💬 |
824 |
Hydrolyzed guar gum |
Guar gum |
1件: D04403 D04403 💬 |
- |
- |
006 1件: 6 💬 |
825 |
I 123 |
Iodide I-123 |
- |
- |
- |
006 1件: 6 💬 |
826 |
I-123 |
Iodide I-123 |
- |
- |
- |
002 2件: 2 , 6 💬 |
827 |
I-123-5-ia85380 |
Iodide I-123 |
- |
- |
- |
006 1件: 6 💬 |
828 |
I123 |
- |
- |
- |
- |
006 1件: 6 💬 |
829 |
Iberogast |
- |
- |
- |
- |
006 1件: 6 💬 |
830 |
Idebenone |
Idebenone |
1件: D01750 D01750 💬 |
- |
- |
006 5件: 6 , 13, 18, 113, 302 💬 |
831 |
Immediate release carbidopa/levodopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
832 |
Immediate release carbidopa/levodopa 10/100 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
833 |
Immediate release carbidopa/levodopa 25/100 mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
834 |
Impact |
- |
- |
- |
- |
006 8件: 6 , 13, 46, 50, 53, 96, 97, 299 💬 |
835 |
Incobotulinum toxin a |
- |
- |
- |
- |
002 3件: 2 , 6 , 13 💬 |
836 |
Incobotulinumtoxina |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
006 1件: 6 💬 |
837 |
Incobotulinumtoxina (100 units) |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
006 1件: 6 💬 |
838 |
Incobotulinumtoxina (75 units) |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
006 1件: 6 💬 |
839 |
Infudopa i.v. |
- |
- |
- |
- |
006 1件: 6 💬 |
840 |
Infudopa s.c. |
- |
- |
- |
- |
006 1件: 6 💬 |
841 |
Infusions of young plasma |
- |
- |
- |
- |
006 1件: 6 💬 |
842 |
Inhaled vr040 |
- |
- |
- |
- |
006 1件: 6 💬 |
843 |
Injection of apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
844 |
Injection of normal saline |
- |
- |
- |
- |
006 1件: 6 💬 |
845 |
Injection of umbilical cord derived mscs |
- |
- |
- |
- |
006 1件: 6 💬 |
846 |
Inosine |
Inosine |
1件: D00054 D00054 💬 |
- |
- |
002 4件: 2 , 6 , 13, 17 💬 |
847 |
Intracerebral microinjections |
- |
- |
- |
- |
006 1件: 6 💬 |
848 |
Intranasal glutathione - (in)gsh |
Glutathione |
2件: D00014 D00014, D00031 D00031 💬 |
- |
- |
006 1件: 6 💬 |
849 |
Intranasal insulin |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
850 |
Intravenous and oral n-acetyl cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
006 1件: 6 💬 |
851 |
Intravenous infusion |
- |
- |
- |
- |
006 1件: 6 💬 |
852 |
Intravenous levodopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
853 |
Intravesical injection of botulinum a toxin |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
854 |
Ioflupane (123i) |
- |
- |
- |
- |
006 1件: 6 💬 |
855 |
Ioflupane 123i (datscan®) |
- |
- |
- |
- |
006 1件: 6 💬 |
856 |
Ioflupane [123 i] |
- |
- |
- |
- |
006 1件: 6 💬 |
857 |
Ioflupane [123i] |
- |
- |
- |
- |
006 1件: 6 💬 |
858 |
Ioflupane i 123 |
Iodide I-123 |
1件: D10014 D10014 💬 |
- |
- |
006 1件: 6 💬 |
859 |
Ipratropium |
Ipratropium |
1件: D02212 D02212 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 2件: 6 , 86 💬 |
860 |
Ipratropium bromide (drug) |
Ipratropium |
1件: D02212 D02212 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
861 |
Iproniazid |
Iproniazid |
1件: D02579 D02579 💬 |
MAOA 2件: MAOA, MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
862 |
Ips-nsc cells |
- |
- |
- |
- |
006 1件: 6 💬 |
863 |
Ipt803 |
- |
- |
- |
- |
006 1件: 6 💬 |
864 |
Ipx054 100 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
865 |
Ipx054 150 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
866 |
Ipx054 200 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
867 |
Ipx054 250 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
868 |
Ipx054 300 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
869 |
Ipx066 |
- |
- |
- |
- |
006 1件: 6 💬 |
870 |
Ipx066 145 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
871 |
Ipx066 145 mg ld |
- |
- |
- |
- |
006 1件: 6 💬 |
872 |
Ipx066 195 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
873 |
Ipx066 195 mg ld |
- |
- |
- |
- |
006 1件: 6 💬 |
874 |
Ipx066 245 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
875 |
Ipx066 245 mg ld |
- |
- |
- |
- |
006 1件: 6 💬 |
876 |
Ipx066 95 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
877 |
Ipx066 95 mg ld |
- |
- |
- |
- |
006 1件: 6 💬 |
878 |
Ipx066-145 |
- |
- |
- |
- |
006 1件: 6 💬 |
879 |
Ipx066-195 |
- |
- |
- |
- |
006 1件: 6 💬 |
880 |
Ipx066-245 |
- |
- |
- |
- |
006 1件: 6 💬 |
881 |
Ipx066-95 |
- |
- |
- |
- |
006 1件: 6 💬 |
882 |
Ipx203 |
- |
- |
- |
- |
006 1件: 6 💬 |
883 |
Ipx203 140 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
884 |
Ipx203 180 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
885 |
Ipx203 210 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
886 |
Ipx203 270 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
887 |
Ipx203 280 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
888 |
Ipx203 350 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
889 |
Ipx203 er cd-ld |
- |
- |
- |
- |
006 1件: 6 💬 |
890 |
Ir cd-ld |
- |
- |
- |
- |
006 1件: 6 💬 |
891 |
Ir cd-ld (carbidopa-levodopa) tablets |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
892 |
Ir ld / cd |
- |
- |
- |
- |
006 1件: 6 💬 |
893 |
Ir ld/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
894 |
Irl752 |
- |
- |
- |
- |
006 1件: 6 💬 |
895 |
Irl790 |
- |
- |
- |
- |
006 1件: 6 💬 |
896 |
Irx4204 |
- |
- |
- |
- |
006 1件: 6 💬 |
897 |
Isc-hpnsc |
- |
- |
- |
- |
006 1件: 6 💬 |
898 |
Isicom |
- |
- |
- |
- |
006 1件: 6 💬 |
899 |
Isoflurane |
Isoflurane |
1件: D00545 D00545 💬 |
- |
- |
006 1件: 6 💬 |
900 |
Isradipine |
Isradipine |
1件: D00349 D00349 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
901 |
Isradipine cr 10mg |
Isradipine |
1件: D00349 D00349 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
902 |
Isradipine cr 20mg |
Isradipine |
1件: D00349 D00349 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
903 |
Isradipine cr 5mg |
Isradipine |
1件: D00349 D00349 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
904 |
Istradefylline |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
905 |
Istradefylline ( kw-6002) |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
906 |
Istradefylline (kw-6002) |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
907 |
Istradefylline 20 mg |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
908 |
Istradefylline 20 mg or 40 mg |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
909 |
Istradefylline 40 mg |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
910 |
Iti-214 |
ITI-214 |
- |
- |
- |
006 1件: 6 💬 |
911 |
Iv apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
912 |
Iv levodopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
913 |
Izd174 |
- |
- |
- |
- |
006 2件: 6 , 106 💬 |
914 |
Jm |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
915 |
Jm-010 |
- |
- |
- |
- |
006 1件: 6 💬 |
916 |
Jm-010 group a |
- |
- |
- |
- |
006 1件: 6 💬 |
917 |
Jm-010 group b |
- |
- |
- |
- |
006 1件: 6 💬 |
918 |
Jnj-31001074 |
- |
- |
- |
- |
006 1件: 6 💬 |
919 |
Jnj31-31001074 |
- |
- |
- |
- |
006 1件: 6 💬 |
920 |
Jp 1730 |
- |
- |
- |
- |
006 1件: 6 💬 |
921 |
Jp-1730/f01 |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
922 |
Jp-1730/f02 |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
923 |
Jp-1730/f03 |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
924 |
Jzp-110 |
- |
- |
- |
- |
006 1件: 6 💬 |
925 |
K0706 |
- |
- |
- |
- |
006 1件: 6 💬 |
926 |
Kdt-3594 |
- |
- |
- |
- |
006 1件: 6 💬 |
927 |
Ketone ester drink |
- |
- |
- |
- |
006 1件: 6 💬 |
928 |
Ketone ester elite endurance nutrition drink |
- |
- |
- |
- |
006 1件: 6 💬 |
929 |
Kinoquinone (proposed) |
- |
- |
- |
- |
006 1件: 6 💬 |
930 |
Km-819 |
- |
- |
- |
- |
006 1件: 6 💬 |
931 |
Kw-6002 |
- |
- |
- |
- |
006 1件: 6 💬 |
932 |
Kw-6002 (istradefylline) |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
933 |
Kw-6356 |
- |
- |
- |
- |
006 1件: 6 💬 |
934 |
Kw-6356 high dose |
- |
- |
- |
- |
006 1件: 6 💬 |
935 |
Kw-6356 low dose |
- |
- |
- |
- |
006 1件: 6 💬 |
936 |
Kw-6356 middle dose |
- |
- |
- |
- |
006 1件: 6 💬 |
937 |
Kw-6356 x dose |
- |
- |
- |
- |
006 1件: 6 💬 |
938 |
Kw-6356 y dose |
- |
- |
- |
- |
006 1件: 6 💬 |
939 |
Kw-6500 |
- |
- |
- |
- |
006 1件: 6 💬 |
940 |
L-123 ioflupane |
- |
- |
- |
- |
006 1件: 6 💬 |
941 |
L-3-(3,4-dihydroxyphenyl)alanine |
Alanine |
1件: D00012 D00012 💬 |
- |
- |
006 1件: 6 💬 |
942 |
L-dopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
943 |
L-dopa/ modopar |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
944 |
L-dops |
Droxidopa |
1件: D01277 D01277 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
945 |
L-methylfolate |
Levomefolic acid |
1件: D09353 D09353 💬 |
- |
- |
006 1件: 6 💬 |
946 |
L-tyrosine |
Tyrosine |
1件: D00022 D00022 💬 |
- |
- |
006 2件: 6 , 111 💬 |
947 |
La |
- |
- |
- |
- |
006 5件: 6 , 13, 75, 76, 222 💬 |
948 |
Lactobacillus casei dg (enterolactis duo®) |
- |
- |
- |
- |
006 1件: 6 💬 |
949 |
Lactobacillus plantarum |
Lactobacillus plantarum |
- |
- |
- |
006 3件: 6 , 97, 156 💬 |
950 |
Lactobacillus plantarum ps128 |
Lactobacillus plantarum |
- |
- |
- |
006 1件: 6 💬 |
951 |
Lactose |
Lactose |
2件: D00046 D00046, D03226 D03226 💬 |
- |
- |
002 6件: 2 , 6 , 13, 97, 228, 310 💬 |
952 |
Lcig |
- |
- |
- |
- |
006 1件: 6 💬 |
953 |
Lcig (duodopa) |
- |
- |
- |
- |
006 1件: 6 💬 |
954 |
Ld / be |
- |
- |
- |
- |
006 1件: 6 💬 |
955 |
Ld+ddci |
- |
- |
- |
- |
006 1件: 6 💬 |
956 |
Ld-ddci |
- |
- |
- |
- |
006 1件: 6 💬 |
957 |
Ld/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
958 |
Leptin |
Leptin |
- |
- |
- |
006 2件: 6 , 265 💬 |
959 |
Leucine |
Leucine |
1件: D00030 D00030 💬 |
- |
- |
005 10件: 5 , 6 , 7 , 19, 96, 97, 127, 283, 284, 299 💬 |
960 |
Levetiracetam |
Levetiracetam |
1件: D00709 D00709 💬 |
SV2A 1件: SV2A 💬 |
ECM-receptor interaction 1件: ECM-receptor interaction |
002 4件: 2 , 4 , 6 , 13 💬 |
961 |
Levodopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
002 8件: 2 , 4 , 6 , 17, 90, 140, 164, 201 💬 |
962 |
Levodopa (dc.it) (fu) |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
963 |
Levodopa (delivered intravenously) |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
964 |
Levodopa (drug), intraduodenal administration |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
965 |
Levodopa (l-dopa) |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
966 |
Levodopa (l-dopa) + standard care |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
967 |
Levodopa / benserazid |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
968 |
Levodopa / benserazide 200 + 50 mg |
Benserazide |
2件: D00059 D00059, D03082 D03082 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
969 |
Levodopa 100 mg / benserazide 25 mg |
Benserazide |
2件: D00059 D00059, D03082 D03082 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
970 |
Levodopa 100 mg a cap |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
971 |
Levodopa 125 mg a cap |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
972 |
Levodopa 150 mg a cap |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
973 |
Levodopa 25mg/100mg |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
974 |
Levodopa 75 mg a cap |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
975 |
Levodopa acute challenge |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
976 |
Levodopa and carbidopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
977 |
Levodopa and carbidopa sc solution |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
978 |
Levodopa and carbidopa solution for sc administration |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
979 |
Levodopa and decarboxylase inhibitor |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
980 |
Levodopa and domperidone |
Domperidone |
3件: D00059 D00059, D01745 D01745, D07868 D07868 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
981 |
Levodopa benserazide madopar |
Benserazide |
2件: D00059 D00059, D03082 D03082 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
982 |
Levodopa benserazide teva italia |
Benserazide |
2件: D00059 D00059, D03082 D03082 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
983 |
Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
984 |
Levodopa carbidopa intestinal gel (lcig) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
985 |
Levodopa cr (controlled release) |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
986 |
Levodopa cyclops |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
987 |
Levodopa dc.it fu |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
988 |
Levodopa dispersible |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
989 |
Levodopa infusion |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
990 |
Levodopa inn |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
991 |
Levodopa mr |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
992 |
Levodopa powder for inhalation |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
993 |
Levodopa tablet |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
994 |
Levodopa, carbidopa, entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
995 |
Levodopa, carbidopa, odm-104 |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
996 |
Levodopa, decarboxylase inhibitor and comt inhibitor |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
997 |
Levodopa-4'-monophosphate |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
998 |
Levodopa-carbidopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 2件: 6 , 90 💬 |
999 |
Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1000 |
Levodopa-carbidopa immediate release (lc-ir) tablets |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1001 |
Levodopa-carbidopa intestinal gel |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1002 |
Levodopa-carbidopa intestinal gel (lcig) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1003 |
Levodopa-carbidopa multilayer extended release tablet |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1004 |
Levodopa-carbidopa xl tablet (m) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1005 |
Levodopa-carbidopa-entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1006 |
Levodopa/benserazide |
Benserazide |
2件: D00059 D00059, D03082 D03082 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1007 |
Levodopa/benserazide 100/25 mg |
Benserazide |
2件: D00059 D00059, D03082 D03082 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1008 |
Levodopa/benzeraside |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1009 |
Levodopa/benzerazide |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1010 |
Levodopa/carbidopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 2件: 6 , 164 💬 |
1011 |
Levodopa/carbidopa (ld/cd) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1012 |
Levodopa/carbidopa (sinemet) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1013 |
Levodopa/carbidopa 100/25 |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1014 |
Levodopa/carbidopa hydrate |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1015 |
Levodopa/carbidopa solution |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1016 |
Levodopa/carbidopa(200mg/50mg) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1017 |
Levodopa/carbidopa/entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1018 |
Levodopa/ddci |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1019 |
Levodopa/dopa decarboxylase inhibitor |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1020 |
Liatermin |
Liatermin |
1件: D04727 D04727 💬 |
- |
- |
006 1件: 6 💬 |
1021 |
Liatermin (r-methugdnf) |
Liatermin |
1件: D04727 D04727 💬 |
- |
- |
006 1件: 6 💬 |
1022 |
Lidocaine |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 10件: 6 , 13, 34, 46, 51, 86, 168, 226, 231, 256 💬 |
1023 |
Lingzhi (ganoderma) |
- |
- |
- |
- |
006 1件: 6 💬 |
1024 |
Lipuro |
- |
- |
- |
- |
006 1件: 6 💬 |
1025 |
Liquigen mct oil |
- |
- |
- |
- |
006 1件: 6 💬 |
1026 |
Liraglutide |
Liraglutide |
1件: D06404 D06404 💬 |
GLP1R 1件: GLP1R 💬 |
Insulin secretion 3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
006 3件: 6 , 75, 193 💬 |
1027 |
Lisparin |
- |
- |
- |
- |
006 1件: 6 💬 |
1028 |
Lisuride |
Lisuride |
2件: D01462 D01462, D08132 D08132 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 2件: 6 , 86 💬 |
1029 |
Lisuride hydrogenmaleate |
Lisuride |
2件: D01462 D01462, D08132 D08132 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1030 |
Lisuride transdermal system |
Lisuride |
2件: D01462 D01462, D08132 D08132 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1031 |
Lisuride tts |
Lisuride |
2件: D01462 D01462, D08132 D08132 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1032 |
Lisuride tts 10cm² |
Lisuride |
2件: D01462 D01462, D08132 D08132 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1033 |
Lisuride tts 20cm² |
Lisuride |
2件: D01462 D01462, D08132 D08132 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1034 |
Lithium |
- |
- |
- |
- |
002 5件: 2 , 5 , 6 , 7 , 8 💬 |
1035 |
Lixisenatide |
Lixisenatide |
1件: D09729 D09729 💬 |
GLP1R 1件: GLP1R 💬 |
Insulin secretion 3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
006 1件: 6 💬 |
1036 |
Local anesthesia (lidocaine hydrochloride) |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 1件: 6 💬 |
1037 |
Local trade name, 2mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1038 |
Local trade name, 4mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1039 |
Local trade name, 8mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1040 |
Lodalès® |
- |
- |
- |
- |
006 1件: 6 💬 |
1041 |
Lodosyn® |
- |
- |
- |
- |
006 1件: 6 💬 |
1042 |
Lovastatin |
Lovastatin |
1件: D00359 D00359 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
006 11件: 6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬 |
1043 |
Low dose affitope® pd03a + adjuvant |
- |
- |
- |
- |
006 1件: 6 💬 |
1044 |
Lu 00-800 |
- |
- |
- |
- |
006 1件: 6 💬 |
1045 |
Lu af28996 |
- |
- |
- |
- |
006 1件: 6 💬 |
1046 |
Lu af82422 |
- |
- |
- |
- |
006 1件: 6 💬 |
1047 |
Lubiprostone |
Lubiprostone |
1件: D04790 D04790 💬 |
CLCN2 1件: CLCN2 💬 |
Mineral absorption 1件: Mineral absorption |
006 4件: 6 , 13, 290, 299 💬 |
1048 |
Ly03003 |
- |
- |
- |
- |
006 1件: 6 💬 |
1049 |
Ly03003 ( rotigotine, extended-release microspheres) |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1050 |
Ly03003 (rotigotine extended release microspheres for intramuscular [im] injection) |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1051 |
Ly03003( the name of rotigotine) |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1052 |
Ly03003(rotigotine,extended-release microspheres) |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1053 |
Ly03009 f1 |
- |
- |
- |
- |
006 1件: 6 💬 |
1054 |
Ly03009 f2 |
- |
- |
- |
- |
006 1件: 6 💬 |
1055 |
Ly03009 f3 |
- |
- |
- |
- |
006 1件: 6 💬 |
1056 |
Ly03009 f4 |
- |
- |
- |
- |
006 1件: 6 💬 |
1057 |
Ly300164 |
- |
- |
- |
- |
006 1件: 6 💬 |
1058 |
Ly3154207 |
- |
- |
- |
- |
006 1件: 6 💬 |
1059 |
Madopar |
- |
- |
- |
- |
006 1件: 6 💬 |
1060 |
Madopar 125 mg, orodispersible tablet |
- |
- |
- |
- |
006 1件: 6 💬 |
1061 |
Madopar 200+50 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1062 |
Madopar lt |
- |
- |
- |
- |
006 1件: 6 💬 |
1063 |
Madopar® 125 |
- |
- |
- |
- |
006 1件: 6 💬 |
1064 |
Madopar® 250 |
- |
- |
- |
- |
006 1件: 6 💬 |
1065 |
Madopar® hbs |
- |
- |
- |
- |
006 1件: 6 💬 |
1066 |
Madopar® hbs 125 |
- |
- |
- |
- |
006 1件: 6 💬 |
1067 |
Magnesium |
Magnesium |
- |
- |
- |
006 16件: 6 , 11, 13, 46, 64, 70, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 💬 |
1068 |
Magnesium oxide |
Magnesium |
1件: D01167 D01167 💬 |
- |
- |
006 3件: 6 , 166, 291 💬 |
1069 |
Maltodextrin |
Maltodextrin |
1件: D02329 D02329 💬 |
- |
- |
006 4件: 6 , 13, 96, 97 💬 |
1070 |
Mannitol |
Mannitol |
1件: D00062 D00062 💬 |
- |
- |
006 4件: 6 , 60, 96, 299 💬 |
1071 |
Mantadix |
- |
- |
- |
- |
006 1件: 6 💬 |
1072 |
Mars |
- |
- |
- |
- |
006 1件: 6 💬 |
1073 |
Masitinib |
Masitinib |
1件: D10229 D10229 💬 |
KIT 1件: KIT 💬 |
Acute myeloid leukemia 11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
002 6件: 2 , 5 , 6 , 13, 46, 96 💬 |
1074 |
Masitinib mesylate |
Masitinib |
1件: D10229 D10229 💬 |
KIT 1件: KIT 💬 |
Acute myeloid leukemia 11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
002 6件: 2 , 5 , 6 , 13, 46, 96 💬 |
1075 |
Mavoglurant |
Mavoglurant |
- |
- |
- |
006 2件: 6 , 206 💬 |
1076 |
Mct |
- |
- |
- |
- |
006 1件: 6 💬 |
1077 |
Me2125 (safinamide mesilate) |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1078 |
Medi1341 |
- |
- |
- |
- |
006 1件: 6 💬 |
1079 |
Melatonin |
Melatonin |
1件: D08170 D08170 💬 |
MTNR1A 2件: MTNR1A, MTNR1B 💬 |
Circadian entrainment 2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
006 11件: 6 , 8 , 13, 46, 49, 90, 97, 144, 145, 149, 202 💬 |
1080 |
Melatonin pr |
Melatonin |
1件: D08170 D08170 💬 |
MTNR1A 2件: MTNR1A, MTNR1B 💬 |
Circadian entrainment 2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
1081 |
Melatonin(circadin®) |
Melatonin |
1件: D08170 D08170 💬 |
MTNR1A 2件: MTNR1A, MTNR1B 💬 |
Circadian entrainment 2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
1082 |
Melevodopa |
Melevodopa |
1件: D07304 D07304 💬 |
- |
- |
006 1件: 6 💬 |
1083 |
Melevodopa and decarboxylase inhibitor |
Melevodopa |
1件: D07304 D07304 💬 |
- |
- |
006 1件: 6 💬 |
1084 |
Melperon |
- |
- |
- |
- |
006 1件: 6 💬 |
1085 |
Melperone |
Melperone |
1件: D07309 D07309 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1086 |
Melperone hcl |
Melperone |
1件: D07309 D07309 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1087 |
Memantin orion |
- |
- |
- |
- |
006 1件: 6 💬 |
1088 |
Memantine |
Memantine |
2件: D04905 D04905, D08174 D08174 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
002 7件: 2 , 6 , 8 , 13, 49, 127, 205 💬 |
1089 |
Memantine (drug) |
Memantine |
2件: D04905 D04905, D08174 D08174 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
1090 |
Memantine hydrochloride |
Memantine |
2件: D04905 D04905, D08174 D08174 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
002 3件: 2 , 6 , 127 💬 |
1091 |
Mesdopetam |
Mesdopetam |
- |
- |
- |
006 1件: 6 💬 |
1092 |
Mesdopetam (irl790) |
Mesdopetam |
- |
- |
- |
006 1件: 6 💬 |
1093 |
Mesencephalic neuronal precursor cells |
- |
- |
- |
- |
006 1件: 6 💬 |
1094 |
Mesenchymal stem cells |
- |
- |
- |
- |
002 11件: 2 , 6 , 13, 20, 49, 51, 60, 96, 222, 274, 299 💬 |
1095 |
Mestinon |
- |
- |
- |
- |
003 3件: 3 , 6 , 11 💬 |
1096 |
Metabolic cofactor supplementation |
- |
- |
- |
- |
006 1件: 6 💬 |
1097 |
Metformin |
Metformin |
2件: D00944 D00944, D04966 D04966 💬 |
PRKAA1 2件: PRKAA1, PRKAA2 💬 |
AMPK signaling pathway 19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
002 21件: 2 , 6 , 13, 46, 49, 60, 67, 75, 77, 81, 86, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 💬 |
1098 |
Methylphenidate |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 7件: 6 , 13, 34, 84, 113, 179, 206 💬 |
1099 |
Methylphenidate (mpd) |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 1件: 6 💬 |
1100 |
Methylphenidate hydrochloride |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 2件: 6 , 13 💬 |
1101 |
Methylprednisolone |
Methylprednisolone |
6件: D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
002 44件: 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
1102 |
Mg |
- |
- |
- |
- |
006 3件: 6 , 13, 51 💬 |
1103 |
Mid dose anavex2-73 |
- |
- |
- |
- |
006 1件: 6 💬 |
1104 |
Midazolam |
Midazolam |
3件: D00550 D00550, D00696 D00696, D05028 D05028 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
002 11件: 2 , 3 , 6 , 13, 21, 46, 70, 96, 97, 231, 298 💬 |
1105 |
Midodrine |
Midodrine |
2件: D01307 D01307, D08220 D08220 💬 |
ADRA1A 3件: ADRA1A, ADRA1B, ADRA1D 💬 |
AMPK signaling pathway 7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
006 3件: 6 , 17, 58 💬 |
1106 |
Minocycline |
Minocycline |
2件: D00850 D00850, D05045 D05045 💬 |
- |
- |
002 13件: 2 , 6 , 8 , 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 💬 |
1107 |
Minodronic acid |
Minodronic acid |
- |
- |
- |
006 4件: 6 , 46, 93, 95 💬 |
1108 |
Mirabegron |
Mirabegron |
1件: D09535 D09535 💬 |
ADRB3 1件: ADRB3 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cGMP-PKG signaling pathway |
006 3件: 6 , 13, 226 💬 |
1109 |
Mirapex |
- |
- |
- |
- |
006 1件: 6 💬 |
1110 |
Mirapex (pramipexole) |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1111 |
Mirapex er |
- |
- |
- |
- |
006 1件: 6 💬 |
1112 |
Mirapex la |
- |
- |
- |
- |
006 1件: 6 💬 |
1113 |
Mirapexin |
- |
- |
- |
- |
006 1件: 6 💬 |
1114 |
Mirapexin / sifrol |
- |
- |
- |
- |
006 1件: 6 💬 |
1115 |
Mirapexin extended release various strengths |
- |
- |
- |
- |
006 1件: 6 💬 |
1116 |
Mirapexin*30cpr 0,7mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1117 |
Mirapexin/sifrol |
- |
- |
- |
- |
006 1件: 6 💬 |
1118 |
Mitoq |
- |
- |
- |
- |
006 3件: 6 , 13, 97 💬 |
1119 |
Mk0657 |
- |
- |
- |
- |
006 1件: 6 💬 |
1120 |
Moclobemide |
Moclobemide |
1件: D02561 D02561 💬 |
MAOA 1件: MAOA 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1121 |
Modafinil |
Modafinil |
1件: D01832 D01832 💬 |
- |
- |
006 4件: 6 , 13, 49, 93 💬 |
1122 |
Modafinil 50mg |
Modafinil |
1件: D01832 D01832 💬 |
- |
- |
006 1件: 6 💬 |
1123 |
Modal |
- |
- |
- |
- |
002 5件: 2 , 6 , 17, 46, 70 💬 |
1124 |
Modiodal |
- |
- |
- |
- |
006 1件: 6 💬 |
1125 |
Modopar |
- |
- |
- |
- |
006 1件: 6 💬 |
1126 |
Monoamine oxidase b inhibitors |
- |
- |
- |
- |
006 1件: 6 💬 |
1127 |
Motilium |
- |
- |
- |
- |
006 2件: 6 , 230 💬 |
1128 |
Moxifloxacin |
Moxifloxacin |
2件: D00874 D00874, D08237 D08237 💬 |
- |
- |
002 8件: 2 , 6 , 46, 49, 85, 86, 240, 299 💬 |
1129 |
Moxifloxacin infusion |
Moxifloxacin |
2件: D00874 D00874, D08237 D08237 💬 |
- |
- |
006 1件: 6 💬 |
1130 |
Moxifloxacina cloridrato |
- |
- |
- |
- |
006 1件: 6 💬 |
1131 |
Msc |
- |
- |
- |
- |
006 6件: 6 , 51, 60, 96, 97, 271 💬 |
1132 |
Muscimol |
Muscimol |
- |
- |
- |
006 1件: 6 💬 |
1133 |
Mémantine |
- |
- |
- |
- |
006 1件: 6 💬 |
1134 |
N acetyl cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
006 2件: 6 , 19 💬 |
1135 |
N-0923 |
- |
- |
- |
- |
006 1件: 6 💬 |
1136 |
N-acetylcysteine |
Acetylcysteine |
1件: D00221 D00221 💬 |
- |
- |
006 10件: 6 , 13, 19, 20, 49, 58, 85, 111, 164, 299 💬 |
1137 |
N-acetylcysteine capsule |
Acetylcysteine |
1件: D00221 D00221 💬 |
- |
- |
006 1件: 6 💬 |
1138 |
N.a. |
- |
- |
- |
- |
003 10件: 3 , 6 , 8 , 13, 46, 96, 97, 240, 256, 271 💬 |
1139 |
N04bd02 |
- |
- |
- |
- |
006 1件: 6 💬 |
1140 |
Nabilone |
Nabilone |
1件: D05099 D05099 💬 |
CNR1 2件: CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
006 2件: 6 , 13 💬 |
1141 |
Nabilone 0.25 mg |
Nabilone |
1件: D05099 D05099 💬 |
CNR1 2件: CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
006 1件: 6 💬 |
1142 |
Nacom |
- |
- |
- |
- |
006 1件: 6 💬 |
1143 |
Nacom 100 |
- |
- |
- |
- |
006 1件: 6 💬 |
1144 |
Nacom levodopa+cardidopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1145 |
Nal |
- |
- |
- |
- |
006 2件: 6 , 299 💬 |
1146 |
Nalmefene |
Nalmefene |
1件: D05111 D05111 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1147 |
Naloxone |
Naloxone |
2件: D01340 D01340, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 2件: 6 , 226 💬 |
1148 |
Naloxone hydrochloride dihydrate |
Naloxone |
2件: D01340 D01340, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1149 |
Naltrexone |
Naltrexone |
2件: D02095 D02095, D05113 D05113 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 12件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬 |
1150 |
Nardil |
- |
- |
- |
- |
006 1件: 6 💬 |
1151 |
Nbtx-001 |
- |
- |
- |
- |
006 1件: 6 💬 |
1152 |
Nd0611 |
- |
- |
- |
- |
006 1件: 6 💬 |
1153 |
Nd0612 |
- |
- |
- |
- |
006 1件: 6 💬 |
1154 |
Nd0612 (levodopa/carbidopa solution) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1155 |
Nd1421 |
- |
- |
- |
- |
006 1件: 6 💬 |
1156 |
Nd1587 |
- |
- |
- |
- |
006 1件: 6 💬 |
1157 |
Nd1589 |
- |
- |
- |
- |
006 1件: 6 💬 |
1158 |
Nd1590 |
- |
- |
- |
- |
006 1件: 6 💬 |
1159 |
Nd1702 |
- |
- |
- |
- |
006 1件: 6 💬 |
1160 |
Nebicapone |
Nebicapone |
- |
- |
- |
006 1件: 6 💬 |
1161 |
Nelotanserin |
Nelotanserin |
1件: D09645 D09645 💬 |
HTR2A 1件: HTR2A 💬 |
Calcium signaling pathway 5件: Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
006 1件: 6 💬 |
1162 |
Neridronic acid |
Neridronic Acid |
- |
- |
- |
006 1件: 6 💬 |
1163 |
Nerixia*im ev 1f 25mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1164 |
Neu-120 |
- |
- |
- |
- |
006 1件: 6 💬 |
1165 |
Neupro |
- |
- |
- |
- |
006 1件: 6 💬 |
1166 |
Neupro (reference) |
- |
- |
- |
- |
006 1件: 6 💬 |
1167 |
Neupro 2 mg/24 h parche transdérmico |
- |
- |
- |
- |
006 1件: 6 💬 |
1168 |
Neupro 2 mg/24 h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1169 |
Neupro 2mg/24 h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1170 |
Neupro 2mg/24h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1171 |
Neupro 4 mg/24 h parche transdérmico |
- |
- |
- |
- |
006 1件: 6 💬 |
1172 |
Neupro 4 mg/24 h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1173 |
Neupro 4mg/24 h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1174 |
Neupro 4mg/24h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1175 |
Neupro 4mg/24hr transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1176 |
Neupro 6 mg/24 h parche transdérmico |
- |
- |
- |
- |
006 1件: 6 💬 |
1177 |
Neupro 6 mg/24 h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1178 |
Neupro 6mg/24 h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1179 |
Neupro 6mg/24h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1180 |
Neupro 8 mg/24 h parche transdérmico |
- |
- |
- |
- |
006 1件: 6 💬 |
1181 |
Neupro 8 mg/24 h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1182 |
Neupro 8mg/24h transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1183 |
Neupro*28cer 2mg/24h |
- |
- |
- |
- |
006 1件: 6 💬 |
1184 |
Neupro*28cer 4mg/24h |
- |
- |
- |
- |
006 1件: 6 💬 |
1185 |
Neupro*28cer 6mg/24h |
- |
- |
- |
- |
006 1件: 6 💬 |
1186 |
Neupro*28cer 8mg/24h |
- |
- |
- |
- |
006 1件: 6 💬 |
1187 |
Neupro*7cer 4mg/24h |
- |
- |
- |
- |
006 1件: 6 💬 |
1188 |
Neupro*7cer 6mg/24h |
- |
- |
- |
- |
006 1件: 6 💬 |
1189 |
Neupro*7cer 8mg/24h |
- |
- |
- |
- |
006 1件: 6 💬 |
1190 |
Neupro® |
- |
- |
- |
- |
006 1件: 6 💬 |
1191 |
Neuraceq |
- |
- |
- |
- |
006 1件: 6 💬 |
1192 |
Neurobloc |
- |
- |
- |
- |
006 1件: 6 💬 |
1193 |
Neuroepo |
- |
- |
- |
- |
006 1件: 6 💬 |
1194 |
Neurohormonal mechanisms |
- |
- |
- |
- |
006 2件: 6 , 127 💬 |
1195 |
Neurpro |
- |
- |
- |
- |
006 1件: 6 💬 |
1196 |
Niacin |
Niacin |
1件: D00049 D00049 💬 |
- |
- |
006 3件: 6 , 78, 265 💬 |
1197 |
Niacinamide |
Nicotinamide |
1件: D00036 D00036 💬 |
- |
- |
005 4件: 5 , 6 , 13, 67 💬 |
1198 |
Nicorette 10mg/ 16 h |
- |
- |
- |
- |
006 1件: 6 💬 |
1199 |
Nicorette 15 mg/ 16 h |
- |
- |
- |
- |
006 1件: 6 💬 |
1200 |
Nicorette 5 mg/ 16 h |
- |
- |
- |
- |
006 1件: 6 💬 |
1201 |
Nicotinamide |
Nicotinamide |
1件: D00036 D00036 💬 |
- |
- |
002 6件: 2 , 6 , 18, 49, 162, 191 💬 |
1202 |
Nicotinamide riboside |
Nicotinamide |
1件: D00036 D00036 💬 |
- |
- |
002 4件: 2 , 6 , 18, 191 💬 |
1203 |
Nicotine |
Nicotine |
3件: D03365 D03365, D05156 D05156, D05157 D05157 💬 |
CHRNA1 16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 |
Alzheimer disease 7件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases |
006 2件: 6 , 84 💬 |
1204 |
Nicotine gum |
Nicotine |
3件: D03365 D03365, D05156 D05156, D05157 D05157 💬 |
CHRNA1 16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 |
Alzheimer disease 7件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases |
006 1件: 6 💬 |
1205 |
Nicotine nasal spray 10 mg/ml (0.5 mg/spray) |
Nicotine |
3件: D03365 D03365, D05156 D05156, D05157 D05157 💬 |
CHRNA1 16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 |
Alzheimer disease 7件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases |
006 1件: 6 💬 |
1206 |
Nicotine patch |
Nicotine |
3件: D03365 D03365, D05156 D05156, D05157 D05157 💬 |
CHRNA1 16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 |
Alzheimer disease 7件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases |
006 2件: 6 , 84 💬 |
1207 |
Nicotine transdermal patch |
Nicotine |
3件: D03365 D03365, D05156 D05156, D05157 D05157 💬 |
CHRNA1 16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 |
Alzheimer disease 7件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases |
006 1件: 6 💬 |
1208 |
Nicotinell |
- |
- |
- |
- |
006 1件: 6 💬 |
1209 |
Nicotinell 17,5 mg/24-stunden-pflaster |
- |
- |
- |
- |
006 1件: 6 💬 |
1210 |
Nicotinell 35 mg/24-stunden-pflaster |
- |
- |
- |
- |
006 1件: 6 💬 |
1211 |
Nilotinib |
Nilotinib |
1件: D08953 D08953 💬 |
ABL1 4件: ABL1, KIT, PDGFRA, PDGFRB 💬 |
Acute myeloid leukemia 32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
006 5件: 6 , 8 , 34, 51, 86 💬 |
1212 |
Nilotinib 150mg oral capsule [tasigna] |
Nilotinib |
1件: D08953 D08953 💬 |
ABL1 4件: ABL1, KIT, PDGFRA, PDGFRB 💬 |
Acute myeloid leukemia 32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
006 1件: 6 💬 |
1213 |
Nilotinib 300mg oral capsule [tasigna] |
Nilotinib |
1件: D08953 D08953 💬 |
ABL1 4件: ABL1, KIT, PDGFRA, PDGFRB 💬 |
Acute myeloid leukemia 32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
006 1件: 6 💬 |
1214 |
Nitrogen |
Nitrogen |
1件: D00083 D00083 💬 |
- |
- |
005 6件: 5 , 6 , 17, 171, 211, 299 💬 |
1215 |
Nly01 |
- |
- |
- |
- |
006 1件: 6 💬 |
1216 |
Nmda |
Ketamine |
2件: D00711 D00711, D08098 D08098 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
1217 |
Normal saline |
- |
- |
- |
- |
006 16件: 6 , 17, 22, 36, 46, 49, 60, 70, 94, 96, 210, 211, 226, 276, 296, 299 💬 |
1218 |
Northera |
- |
- |
- |
- |
006 1件: 6 💬 |
1219 |
Nortriptyline |
Nortriptyline |
2件: D00816 D00816, D08288 D08288 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6 , 226 💬 |
1220 |
Nortriptyline hydrochloride |
Nortriptyline |
2件: D00816 D00816, D08288 D08288 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 1件: 6 💬 |
1221 |
Npc transplantation |
- |
- |
- |
- |
006 1件: 6 💬 |
1222 |
Nr2b nmda antagonist cp-101,606 (traxoprodil) |
Ketamine |
2件: D00711 D00711, D08098 D08098 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
1223 |
Ns 2330 |
- |
- |
- |
- |
006 1件: 6 💬 |
1224 |
Ns2330 |
- |
- |
- |
- |
006 1件: 6 💬 |
1225 |
Nt 101 |
- |
- |
- |
- |
005 4件: 5 , 6 , 7 , 17 💬 |
1226 |
Ntcell implantation |
- |
- |
- |
- |
006 1件: 6 💬 |
1227 |
Null |
- |
- |
- |
- |
006 16件: 6 , 13, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 💬 |
1228 |
Nw-1015 |
- |
- |
- |
- |
006 1件: 6 💬 |
1229 |
Nw-1015e, emd 1195686, msc2191632b |
- |
- |
- |
- |
006 1件: 6 💬 |
1230 |
Nyx-458 |
- |
- |
- |
- |
006 1件: 6 💬 |
1231 |
Oc oral solution treatment a |
- |
- |
- |
- |
006 1件: 6 💬 |
1232 |
Oc oral solution treatment b |
- |
- |
- |
- |
006 1件: 6 💬 |
1233 |
Oc oral solution treatment c |
- |
- |
- |
- |
006 1件: 6 💬 |
1234 |
Oc oral solution treatment d |
- |
- |
- |
- |
006 1件: 6 💬 |
1235 |
Odm-101 |
- |
- |
- |
- |
006 1件: 6 💬 |
1236 |
Odm-101 105mg carbidopa |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1237 |
Odm-101 65mg carbidopa |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1238 |
Odm-104 |
- |
- |
- |
- |
006 1件: 6 💬 |
1239 |
Omeprazole |
Omeprazole |
4件: D00455 D00455, D01207 D01207, D05259 D05259, D05261 D05261 💬 |
ATP4A 2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
006 16件: 6 , 8 , 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 💬 |
1240 |
Onabotulinumtoxin a injection |
- |
- |
- |
- |
006 1件: 6 💬 |
1241 |
Onabotulinumtoxina |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
006 3件: 6 , 13, 226 💬 |
1242 |
Ondansetron |
Ondansetron |
2件: D00456 D00456, D00678 D00678 💬 |
HTR3A 5件: HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Taste transduction |
006 3件: 6 , 97, 231 💬 |
1243 |
Ondansetron 8 mg film-coated tablets |
Ondansetron |
2件: D00456 D00456, D00678 D00678 💬 |
HTR3A 5件: HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Taste transduction |
006 1件: 6 💬 |
1244 |
Ondansetron hydrochloride dihydrate |
Ondansetron |
2件: D00456 D00456, D00678 D00678 💬 |
HTR3A 5件: HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Taste transduction |
006 2件: 6 , 97 💬 |
1245 |
Ongentys |
- |
- |
- |
- |
006 1件: 6 💬 |
1246 |
Ono-2160/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
1247 |
Ono-2370 |
- |
- |
- |
- |
006 1件: 6 💬 |
1248 |
Ono-2506po |
- |
- |
- |
- |
002 2件: 2 , 6 💬 |
1249 |
Opc |
- |
- |
- |
- |
006 1件: 6 💬 |
1250 |
Opicapone |
Opicapone |
1件: D10825 D10825 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
1251 |
Opicapone (opc) |
Opicapone |
1件: D10825 D10825 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
1252 |
Optimal drug therapy |
- |
- |
- |
- |
006 1件: 6 💬 |
1253 |
Optimized antiparkinsonian treatment |
- |
- |
- |
- |
006 1件: 6 💬 |
1254 |
Oral escitalopram |
Escitalopram |
3件: D02567 D02567, D07704 D07704, D07913 D07913 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 1件: 6 💬 |
1255 |
Oral levodopa and carbidopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1256 |
Oral levodopa/carbidopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1257 |
Orally disintegrating selegiline (zelapar) |
Selegiline |
2件: D00785 D00785, D03731 D03731 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1258 |
Osu 6162 similar to (-)-osu 6162 |
- |
- |
- |
- |
006 1件: 6 💬 |
1259 |
Osu6162 similar to (-)-osu 6162 |
- |
- |
- |
- |
006 2件: 6 , 8 💬 |
1260 |
Other nervous system drugs |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
1261 |
Other parkinson's disease treatments |
- |
- |
- |
- |
006 1件: 6 💬 |
1262 |
Other: [11c]donepezil pet |
Donepezil |
2件: D00670 D00670, D07869 D07869 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
1263 |
Other: balance |
Isoxaflutole |
- |
- |
- |
006 3件: 6 , 13, 299 💬 |
1264 |
Other: balance exercise |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
1265 |
Other: balance training |
Isoxaflutole |
- |
- |
- |
006 2件: 6 , 13 💬 |
1266 |
Other: berg balance scale |
Isoxaflutole |
- |
- |
- |
006 2件: 6 , 13 💬 |
1267 |
Other: best medical treatment |
- |
- |
- |
- |
006 1件: 6 💬 |
1268 |
Other: collection of csf, blood, urine, saliva |
- |
- |
- |
- |
006 1件: 6 💬 |
1269 |
Other: computer game based balance and walking rehabilitation for individuals with parkinson's disease |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
1270 |
Other: control |
- |
- |
- |
- |
006 8件: 6 , 19, 70, 75, 85, 97, 162, 193 💬 |
1271 |
Other: controlled environment tests (series of tasks of everyday life) |
- |
- |
- |
- |
006 1件: 6 💬 |
1272 |
Other: controls primary cervical dystonia (trihexyphenidyl) |
Trihexyphenidyl |
2件: D00787 D00787, D08638 D08638 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
1273 |
Other: data capture |
Bifenthrin |
- |
- |
- |
006 1件: 6 💬 |
1274 |
Other: diary completion |
- |
- |
- |
- |
006 1件: 6 💬 |
1275 |
Other: dyt 1 dystonia |
- |
- |
- |
- |
006 1件: 6 💬 |
1276 |
Other: dyt 1 dystonia (healthy control) |
- |
- |
- |
- |
006 1件: 6 💬 |
1277 |
Other: endurance |
- |
- |
- |
- |
006 1件: 6 💬 |
1278 |
Other: evaluation by investigator |
- |
- |
- |
- |
006 1件: 6 💬 |
1279 |
Other: event-related evoked potential using electroencephalography (eeg). |
- |
- |
- |
- |
006 1件: 6 💬 |
1280 |
Other: fog |
- |
- |
- |
- |
006 1件: 6 💬 |
1281 |
Other: four square step test |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
1282 |
Other: functional mobility |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
1283 |
Other: functional reach test |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
1284 |
Other: gait and balance group training |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
1285 |
Other: hemicellulose crystalline |
- |
- |
- |
- |
006 1件: 6 💬 |
1286 |
Other: high intensity exercise and balance training |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
1287 |
Other: hoehn and yahr scale |
- |
- |
- |
- |
006 1件: 6 💬 |
1288 |
Other: imitation surgical procedure (isp) |
- |
- |
- |
- |
006 1件: 6 💬 |
1289 |
Other: lower limb strength |
- |
- |
- |
- |
006 1件: 6 💬 |
1290 |
Other: mibg label with i123 or i124 |
- |
- |
- |
- |
006 1件: 6 💬 |
1291 |
Other: mobile platform exercise |
- |
- |
- |
- |
006 1件: 6 💬 |
1292 |
Other: motor assessments before taking regular pd treatment |
- |
- |
- |
- |
006 1件: 6 💬 |
1293 |
Other: motor assessments on regular pd treatment |
- |
- |
- |
- |
006 1件: 6 💬 |
1294 |
Other: mp+ddci |
- |
- |
- |
- |
006 1件: 6 💬 |
1295 |
Other: mp-equivalent |
- |
- |
- |
- |
006 1件: 6 💬 |
1296 |
Other: mp-low |
- |
- |
- |
- |
006 1件: 6 💬 |
1297 |
Other: mri |
- |
- |
- |
- |
006 3件: 6 , 127, 206 💬 |
1298 |
Other: multidisciplinary intensive rehabilitation treatment |
- |
- |
- |
- |
006 1件: 6 💬 |
1299 |
Other: music |
- |
- |
- |
- |
006 1件: 6 💬 |
1300 |
Other: neupro 4 mg / 24 hr. transdermal patch |
- |
- |
- |
- |
006 1件: 6 💬 |
1301 |
Other: non-motor symptoms |
- |
- |
- |
- |
006 1件: 6 💬 |
1302 |
Other: nordic walking (only osteoporosis group) |
- |
- |
- |
- |
006 1件: 6 💬 |
1303 |
Other: observational cohort |
- |
- |
- |
- |
006 1件: 6 💬 |
1304 |
Other: optional blood-oxygen-level dependent functionalmri |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
006 1件: 6 💬 |
1305 |
Other: parkinson mpower mobile application |
- |
- |
- |
- |
006 1件: 6 💬 |
1306 |
Other: pd exercise intervention |
- |
- |
- |
- |
006 1件: 6 💬 |
1307 |
Other: pd vitamin + exercise |
- |
- |
- |
- |
006 1件: 6 💬 |
1308 |
Other: physical function performance test |
- |
- |
- |
- |
006 1件: 6 💬 |
1309 |
Other: physical therapy |
- |
- |
- |
- |
006 2件: 6 , 70 💬 |
1310 |
Other: pittsburgh compound b [11c]-pib |
Pittsburgh Compound B |
- |
- |
- |
006 1件: 6 💬 |
1311 |
Other: questionnaires |
- |
- |
- |
- |
006 5件: 6 , 13, 41, 93, 96 💬 |
1312 |
Other: recommendation with regard to nutrition |
- |
- |
- |
- |
006 1件: 6 💬 |
1313 |
Other: rhythmic auditory stimulation (ras) |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
1314 |
Other: rhythmic balance-movement training (rbmt) |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
1315 |
Other: rotigotine |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1316 |
Other: saline |
- |
- |
- |
- |
002 8件: 2 , 6 , 46, 97, 98, 256, 274, 301 💬 |
1317 |
Other: screening to prevent falls |
- |
- |
- |
- |
006 1件: 6 💬 |
1318 |
Other: sham group |
- |
- |
- |
- |
006 1件: 6 💬 |
1319 |
Other: sham surgery |
- |
- |
- |
- |
006 1件: 6 💬 |
1320 |
Other: smartphone-based balance exercises |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
1321 |
Other: specific sl-therapy |
- |
- |
- |
- |
006 1件: 6 💬 |
1322 |
Other: standardized scales: mds-updrs (part ii to iv) and rdrs |
- |
- |
- |
- |
006 1件: 6 💬 |
1323 |
Other: stool sample |
- |
- |
- |
- |
006 2件: 6 , 299 💬 |
1324 |
Other: t-dcs group |
- |
- |
- |
- |
006 1件: 6 💬 |
1325 |
Other: tampa kinesiophobia scale, berg-balance test, international physical activity questionnaire-short form, falls efficacy scale |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
1326 |
Other: the timed 360° turn test |
- |
- |
- |
- |
006 1件: 6 💬 |
1327 |
Other: timed up and go test |
- |
- |
- |
- |
006 1件: 6 💬 |
1328 |
Other: trunk impairment scale |
- |
- |
- |
- |
006 1件: 6 💬 |
1329 |
Other: tyramine |
Tyramine |
- |
- |
- |
006 1件: 6 💬 |
1330 |
Other: unified parkinson's disease rating scale |
- |
- |
- |
- |
006 1件: 6 💬 |
1331 |
Other: usual care arm exercise |
- |
- |
- |
- |
006 1件: 6 💬 |
1332 |
Other: usual drug treatment of parkinson's disease |
- |
- |
- |
- |
006 1件: 6 💬 |
1333 |
Other: voluntary cough test |
- |
- |
- |
- |
006 1件: 6 💬 |
1334 |
Over-encapsulated entacapone tablets |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
1335 |
Over-encapsulated modafinil |
Modafinil |
1件: D01832 D01832 💬 |
- |
- |
006 1件: 6 💬 |
1336 |
Oxaloacetate (oaa) |
- |
- |
- |
- |
006 1件: 6 💬 |
1337 |
Oxb-102 |
- |
- |
- |
- |
006 1件: 6 💬 |
1338 |
Oxn 10 mg / 5 mg pr |
- |
- |
- |
- |
006 1件: 6 💬 |
1339 |
Oxn 20 mg / 10 mg pr |
- |
- |
- |
- |
006 1件: 6 💬 |
1340 |
Oxn 5 mg/2.5 mg pr |
- |
- |
- |
- |
006 1件: 6 💬 |
1341 |
Oxybate |
gamma-Hydroxybutyric acid |
- |
- |
- |
006 2件: 6 , 149 💬 |
1342 |
Oxybuprocaine |
Oxybuprocaine |
2件: D01768 D01768, D08319 D08319 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 1件: 6 💬 |
1343 |
Oxybutynin |
Oxybutynin |
2件: D00465 D00465, D00722 D00722 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 2件: 6 , 13 💬 |
1344 |
Oxybutynin and darifenacin |
Darifenacin |
4件: D00465 D00465, D00722 D00722, D01699 D01699, D03654 D03654 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
1345 |
Oxybutynin hydrochloride |
Oxybutynin |
2件: D00465 D00465, D00722 D00722 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 2件: 6 , 13 💬 |
1346 |
Oxycodone |
Oxycodone |
3件: D03783 D03783, D05312 D05312, D05462 D05462 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 7件: 6 , 13, 46, 70, 226, 231, 298 💬 |
1347 |
Oxycodone hydrochloride |
Oxycodone |
3件: D03783 D03783, D05312 D05312, D05462 D05462 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 4件: 6 , 70, 226, 298 💬 |
1348 |
Oxycodone/naloxone prolonged release tablets |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1349 |
Oxycodone/naloxone prolonged release tablets 10 mg /5 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1350 |
Oxycodone/naloxone prolonged release tablets 20 mg /10 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1351 |
Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1352 |
Oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
006 18件: 6 , 13, 19, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 294, 299, 330 💬 |
1353 |
Oxytocin |
Oxytocin |
1件: D00089 D00089 💬 |
OXTR 1件: OXTR 💬 |
Calcium signaling pathway 4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway |
006 5件: 6 , 127, 193, 206, 226 💬 |
1354 |
Oxytocin synthetic |
Oxytocin |
1件: D00089 D00089 💬 |
OXTR 1件: OXTR 💬 |
Calcium signaling pathway 4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1355 |
P2b001 |
- |
- |
- |
- |
006 1件: 6 💬 |
1356 |
P2b001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), |
Pramipexole |
5件: D00559 D00559, D02562 D02562, D05575 D05575, D08469 D08469, D10829 D10829 💬 |
DRD2 4件: DRD2, DRD3, DRD4, MAOB 💬 |
Alcoholism 18件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1357 |
P2b001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), |
Pramipexole |
5件: D00559 D00559, D02562 D02562, D05575 D05575, D08469 D08469, D10829 D10829 💬 |
DRD2 4件: DRD2, DRD3, DRD4, MAOB 💬 |
Alcoholism 18件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1358 |
Paracetamol |
Acetaminophen |
1件: D00217 D00217 💬 |
PTGS1 2件: PTGS1, PTGS2 💬 |
Alzheimer disease 23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
003 5件: 3 , 6 , 13, 35, 46 💬 |
1359 |
Parapres |
- |
- |
- |
- |
006 1件: 6 💬 |
1360 |
Parcopa |
- |
- |
- |
- |
006 1件: 6 💬 |
1361 |
Pardaprunox |
- |
- |
- |
- |
006 1件: 6 💬 |
1362 |
Pardoprunox |
Pardoprunox |
1件: D09397 D09397 💬 |
DRD2 3件: DRD2, DRD3, HTR1A 💬 |
Alcoholism 10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
1363 |
Pardoprunox hydrochloride |
Pardoprunox |
1件: D09397 D09397 💬 |
DRD2 3件: DRD2, DRD3, HTR1A 💬 |
Alcoholism 10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
1364 |
Paroxetine |
Paroxetine |
4件: D02260 D02260, D02362 D02362, D05374 D05374, D05375 D05375 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 3件: 6 , 13, 46 💬 |
1365 |
Part 1, jm-010 component group a |
- |
- |
- |
- |
006 1件: 6 💬 |
1366 |
Part 1, jm-010 component group b |
- |
- |
- |
- |
006 1件: 6 💬 |
1367 |
Part 1, jm-010 component group c |
- |
- |
- |
- |
006 1件: 6 💬 |
1368 |
Part 2, jm-010 combination group a |
- |
- |
- |
- |
006 1件: 6 💬 |
1369 |
Part 2, jm-010 combination group b |
- |
- |
- |
- |
006 1件: 6 💬 |
1370 |
Part 2, jm-010 component group c |
- |
- |
- |
- |
006 1件: 6 💬 |
1371 |
Pat |
- |
- |
- |
- |
006 3件: 6 , 13, 160 💬 |
1372 |
Pbf-509 |
- |
- |
- |
- |
006 1件: 6 💬 |
1373 |
Pd patients h&y=1.5-2 medications off |
- |
- |
- |
- |
006 1件: 6 💬 |
1374 |
Pd patients h&y=1.5-2 medications on |
- |
- |
- |
- |
006 1件: 6 💬 |
1375 |
Pd patients h&y=3 medications off |
- |
- |
- |
- |
006 1件: 6 💬 |
1376 |
Pd patients h&y=3 medications on |
- |
- |
- |
- |
006 1件: 6 💬 |
1377 |
Pd vitamin supplementation |
- |
- |
- |
- |
006 1件: 6 💬 |
1378 |
Peg |
- |
- |
- |
- |
006 9件: 6 , 13, 46, 65, 78, 96, 97, 240, 299 💬 |
1379 |
Perampanel |
Perampanel |
1件: D08964 D08964 💬 |
GRIA1 4件: GRIA1, GRIA2, GRIA3, GRIA4 💬 |
Amphetamine addiction 16件: Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway |
002 3件: 2 , 6 , 144 💬 |
1380 |
Pergolide |
Pergolide |
2件: D00502 D00502, D08339 D08339 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1381 |
Pet |
- |
- |
- |
- |
006 1件: 6 💬 |
1382 |
Pf-06412562 |
- |
- |
- |
- |
006 1件: 6 💬 |
1383 |
Pf-06649751 |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1384 |
Pf-06649751 - 15mg |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1385 |
Pf-06649751 - 1mg |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1386 |
Pf-06649751 - 5mg |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1387 |
Pf-06649751 high dose (15 mg qd) |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1388 |
Pf-06649751 low dose (1 mg qd) |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1389 |
Pf-06649751 middle dose 1 (3 mg qd) |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1390 |
Pf-06649751 middle dose 2 (7 mg qd) |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1391 |
Pf-06669571 |
- |
- |
- |
- |
006 1件: 6 💬 |
1392 |
Ph. eur.: (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid |
Propanoic acid |
1件: D02310 D02310 💬 |
- |
- |
006 1件: 6 💬 |
1393 |
Ph. eur.: (2s)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid |
- |
- |
- |
- |
006 1件: 6 💬 |
1394 |
Phenlarmide tablets |
- |
- |
- |
- |
006 1件: 6 💬 |
1395 |
Phenylbutyrate |
Phenylbutyric acid |
1件: D05868 D05868 💬 |
- |
- |
002 11件: 2 , 3 , 6 , 8 , 15, 93, 94, 244, 251, 297, 299 💬 |
1396 |
Pheur.: (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid |
Propanoic acid |
1件: D02310 D02310 💬 |
- |
- |
006 1件: 6 💬 |
1397 |
Pheur.: (2s)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid |
- |
- |
- |
- |
006 1件: 6 💬 |
1398 |
Piclozotan |
Piclozotan |
- |
- |
- |
006 1件: 6 💬 |
1399 |
Pilocarpine |
Pilocarpine |
3件: D00525 D00525, D02200 D02200, D05478 D05478 💬 |
CHRM2 2件: CHRM2, CHRM3 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 3件: 6 , 53, 299 💬 |
1400 |
Pimavanserin |
Pimavanserin |
- |
- |
- |
006 1件: 6 💬 |
1401 |
Pimavanserin (acp-103) |
Pimavanserin |
- |
- |
- |
006 1件: 6 💬 |
1402 |
Pimavanserin tartrate |
Pimavanserin |
- |
- |
- |
006 1件: 6 💬 |
1403 |
Pimavanserin tartrate (acp-103) |
Pimavanserin |
- |
- |
- |
006 1件: 6 💬 |
1404 |
Pioglitazone |
Pioglitazone |
2件: D00945 D00945, D08378 D08378 💬 |
PPARG 1件: PPARG 💬 |
AMPK signaling pathway 9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
002 17件: 2 , 6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬 |
1405 |
Piribedil |
Piribedil |
1件: D07305 D07305 💬 |
DRD2 2件: DRD2, DRD3 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1406 |
Piribedil (clarium) |
Piribedil |
1件: D07305 D07305 💬 |
DRD2 2件: DRD2, DRD3 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1407 |
Pitolisant |
Pitolisant |
1件: D10749 D10749 💬 |
HRH3 1件: HRH3 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 2件: 6 , 193 💬 |
1408 |
Pittsburgh compound b |
Pittsburgh Compound B |
- |
- |
- |
006 2件: 6 , 127 💬 |
1409 |
Pk-merz |
- |
- |
- |
- |
006 1件: 6 💬 |
1410 |
Pk-merz® 200mg/500ml inj(amantadine) , normal saline 500ml inj |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
1411 |
Placebo |
- |
- |
- |
- |
003 26件: 3 , 5 , 6 , 13, 14, 37, 40, 46, 49, 50, 51, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 💬 |
1412 |
Plantago ovata husk |
- |
- |
- |
- |
006 1件: 6 💬 |
1413 |
Posiphen |
Posiphen |
- |
- |
- |
006 1件: 6 💬 |
1414 |
Positron emission tomography using [11 carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11c]-dasb) and [18 fluorine]-altanserin ([18f]-altanserin) |
Activated charcoal |
1件: D03251 D03251 💬 |
- |
- |
006 1件: 6 💬 |
1415 |
Positron emission tomography using [18 fluorine]-altanserin ([18f]-altanserin) |
- |
- |
- |
- |
006 1件: 6 💬 |
1416 |
Pr oxycodone |
Oxycodone |
3件: D03783 D03783, D05312 D05312, D05462 D05462 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1417 |
Pr001a |
- |
- |
- |
- |
006 1件: 6 💬 |
1418 |
Pramipexol |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1419 |
Pramipexol extended release |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1420 |
Pramipexol immediate release |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1421 |
Pramipexole |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
002 2件: 2 , 6 💬 |
1422 |
Pramipexole 0.125 mg tablets |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1423 |
Pramipexole 0.5 mg tablets |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1424 |
Pramipexole dihydrochloride |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1425 |
Pramipexole dihydrochloride extended-release tablets |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1426 |
Pramipexole dihydrochloride monohydrate |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1427 |
Pramipexole dihydrochloride monohydrate extended release |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1428 |
Pramipexole er |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1429 |
Pramipexole extended release |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1430 |
Pramipexole extended release tablet |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1431 |
Pramipexole hydrochloride sustained-release tablet (siforl®) specification: 0.26mg/ tablet (in pramipexole) |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1432 |
Pramipexole immediate release |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1433 |
Pramipexole immediate release tablet |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1434 |
Pramipexole ir |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1435 |
Pramipexole or ropinirole |
Pramipexole |
4件: D00559 D00559, D00784 D00784, D05575 D05575, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1436 |
Pramipexole sr |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1437 |
Praxol hydrochloride sustained release tablet specification: 0.375mg/ tablet (in pramipexole hydrochloride) |
Pramipexole |
2件: D00559 D00559, D05575 D05575 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1438 |
Prednisone |
Prednisone |
1件: D00473 D00473 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
002 47件: 2 , 6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬 |
1439 |
Preladenant |
Preladenant |
1件: D09717 D09717 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
1440 |
Preladenant 10 mg tablet |
Preladenant |
1件: D09717 D09717 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
1441 |
Preladenant 2 mg tablet |
Preladenant |
1件: D09717 D09717 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
1442 |
Preladenant 5 mg tablet |
Preladenant |
1件: D09717 D09717 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
1443 |
Premarin ® |
- |
- |
- |
- |
006 1件: 6 💬 |
1444 |
Pridia (donepezil hydrochloride) 5mg |
Donepezil |
2件: D00670 D00670, D07869 D07869 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
1445 |
Pridia 10mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1446 |
Pridia 5mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1447 |
Pridopidine |
Pridopidine |
1件: D09953 D09953 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
002 3件: 2 , 6 , 8 💬 |
1448 |
Prim-dj2727 |
- |
- |
- |
- |
006 2件: 6 , 97 💬 |
1449 |
Primary cervical dystonia (trihexyphenidyl) |
Trihexyphenidyl |
2件: D00787 D00787, D08638 D08638 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
1450 |
Primavanserin tartrate |
- |
- |
- |
- |
006 1件: 6 💬 |
1451 |
Prior donepezil 5mg |
Donepezil |
2件: D00670 D00670, D07869 D07869 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
1452 |
Prior donzepezil 10mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1453 |
Probiotic |
- |
- |
- |
- |
002 7件: 2 , 6 , 93, 96, 97, 193, 266 💬 |
1454 |
Probiotic capsule |
- |
- |
- |
- |
006 1件: 6 💬 |
1455 |
Probiotics with prebiotic |
- |
- |
- |
- |
006 1件: 6 💬 |
1456 |
Procedure: [123i]-ibzm imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
1457 |
Procedure: [123i]beta-cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
1458 |
Procedure: [123i]ß-cit and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
1459 |
Procedure: biofluid samplings |
- |
- |
- |
- |
006 1件: 6 💬 |
1460 |
Procedure: blood analysis |
- |
- |
- |
- |
006 1件: 6 💬 |
1461 |
Procedure: blood draw |
- |
- |
- |
- |
006 5件: 6 , 19, 65, 231, 299 💬 |
1462 |
Procedure: cardiac monitoring |
- |
- |
- |
- |
006 1件: 6 💬 |
1463 |
Procedure: datscan and spect imaging |
- |
- |
- |
- |
006 1件: 6 💬 |
1464 |
Procedure: electroacupuncture |
- |
- |
- |
- |
006 2件: 6 , 70 💬 |
1465 |
Procedure: embryonic dopamine cell implant surgery |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1466 |
Procedure: exergame |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
1467 |
Procedure: fluoroscopic swallow evaluation |
- |
- |
- |
- |
006 1件: 6 💬 |
1468 |
Procedure: home based balance training |
Isoxaflutole |
- |
- |
- |
006 2件: 6 , 13 💬 |
1469 |
Procedure: lumbar puncture |
- |
- |
- |
- |
006 5件: 6 , 13, 19, 96, 97 💬 |
1470 |
Procedure: meg |
- |
- |
- |
- |
006 1件: 6 💬 |
1471 |
Procedure: motion analysis |
- |
- |
- |
- |
006 1件: 6 💬 |
1472 |
Procedure: percutaneous endoscopic gastrostomy with jejunal extension (peg-j) |
- |
- |
- |
- |
006 1件: 6 💬 |
1473 |
Procedure: pet/ct |
- |
- |
- |
- |
006 1件: 6 💬 |
1474 |
Procedure: physical exam and updrs part iii assessment |
- |
- |
- |
- |
006 1件: 6 💬 |
1475 |
Procedure: sedation with iv propofol |
Propofol |
1件: D00549 D00549 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 1件: 6 💬 |
1476 |
Procedure: sham surgery |
- |
- |
- |
- |
006 1件: 6 💬 |
1477 |
Procedure: static, dynamic and functional balance exercises |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
1478 |
Procedure: static, dynamic and functional balance exercises with dual task |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
1479 |
Procedure: tissue samplings |
- |
- |
- |
- |
006 1件: 6 💬 |
1480 |
Procedure: umbilical cord blood therapy |
Umbilical Cord Blood Hematopoietic Stem Cells |
- |
- |
- |
002 2件: 2 , 6 💬 |
1481 |
Prolonged release tablet |
- |
- |
- |
- |
006 1件: 6 💬 |
1482 |
Prolopa® |
- |
- |
- |
- |
006 1件: 6 💬 |
1483 |
Propanoic acid |
Propanoic acid |
1件: D02310 D02310 💬 |
- |
- |
006 2件: 6 , 271 💬 |
1484 |
Propofol |
Propofol |
1件: D00549 D00549 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 8件: 6 , 21, 22, 34, 46, 84, 98, 296 💬 |
1485 |
Propofol-lipuro |
Propofol |
1件: D00549 D00549 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 1件: 6 💬 |
1486 |
Propranolol |
Propranolol |
2件: D00483 D00483, D08443 D08443 💬 |
ADRB1 3件: ADRB1, ADRB2, ADRB3 💬 |
Adrenergic signaling in cardiomyocytes 11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 5件: 6 , 158, 167, 227, 278 💬 |
1487 |
Propranolol hcl cf 40 mg tablet |
Propranolol |
2件: D00483 D00483, D08443 D08443 💬 |
ADRB1 3件: ADRB1, ADRB2, ADRB3 💬 |
Adrenergic signaling in cardiomyocytes 11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1488 |
Prosavin |
- |
- |
- |
- |
006 1件: 6 💬 |
1489 |
Proscar*30cpr riv 5mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1490 |
Prx002 |
- |
- |
- |
- |
006 1件: 6 💬 |
1491 |
Prx002, elt2, anti-alpha-synuclein monoclonal antibody |
- |
- |
- |
- |
006 1件: 6 💬 |
1492 |
Pt320 2.0 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1493 |
Pt320 2.5 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1494 |
Pxt002331 |
- |
- |
- |
- |
006 1件: 6 💬 |
1495 |
Pxt002331 - 20mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1496 |
Pxt002331 - dose 1 |
- |
- |
- |
- |
006 1件: 6 💬 |
1497 |
Pxt002331 - dose 2 |
- |
- |
- |
- |
006 1件: 6 💬 |
1498 |
Pym50028 |
- |
- |
- |
- |
006 1件: 6 💬 |
1499 |
Pyridostigmine |
Pyridostigmine |
1件: D00487 D00487 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
003 4件: 3 , 6 , 11, 256 💬 |
1500 |
Pyridostigmine bromide |
Pyridostigmine |
1件: D00487 D00487 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
003 3件: 3 , 6 , 256 💬 |
1501 |
Quetiapine |
Quetiapine |
2件: D00458 D00458, D08456 D08456 💬 |
DRD2 2件: DRD2, HTR2A 💬 |
Alcoholism 11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
006 2件: 6 , 13 💬 |
1502 |
R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride |
Benzofuran |
- |
- |
- |
006 1件: 6 💬 |
1503 |
R-methugdnf |
Liatermin |
1件: D04727 D04727 💬 |
- |
- |
006 1件: 6 💬 |
1504 |
Raav-gad |
- |
- |
- |
- |
006 1件: 6 💬 |
1505 |
Raclopride |
Raclopride |
- |
- |
- |
005 4件: 5 , 6 , 7 , 17 💬 |
1506 |
Racol |
- |
- |
- |
- |
006 3件: 6 , 96, 291 💬 |
1507 |
Radiation: [18-fluorine] flubatine pet scan |
- |
- |
- |
- |
006 1件: 6 💬 |
1508 |
Radiation: fluoroscopy |
- |
- |
- |
- |
006 1件: 6 💬 |
1509 |
Radiation: h215o pet |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
1510 |
Radiation: pet with the tracer 11c-pe2i |
- |
- |
- |
- |
006 1件: 6 💬 |
1511 |
Radiation: pet with the tracer 18f-dpa-714 |
- |
- |
- |
- |
006 1件: 6 💬 |
1512 |
Radiation: radiosurgical thalamotomy |
- |
- |
- |
- |
006 1件: 6 💬 |
1513 |
Radiation: videofluoroscopic swallow evaluation |
- |
- |
- |
- |
006 1件: 6 💬 |
1514 |
Ramelteon |
Ramelteon |
1件: D02689 D02689 💬 |
MTNR1A 2件: MTNR1A, MTNR1B 💬 |
Circadian entrainment 2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
006 3件: 6 , 8 , 46 💬 |
1515 |
Ras |
- |
- |
- |
- |
006 3件: 6 , 13, 66 💬 |
1516 |
Rasagilin |
- |
- |
- |
- |
005 2件: 5 , 6 💬 |
1517 |
Rasagilina |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 2件: 6 , 17 💬 |
1518 |
Rasagilina mesilato |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 2件: 6 , 17 💬 |
1519 |
Rasagilina mesilato (12 weeks) |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1520 |
Rasagiline |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
002 4件: 2 , 5 , 6 , 17 💬 |
1521 |
Rasagiline 1 mg capsule |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1522 |
Rasagiline 1mg tablet |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1523 |
Rasagiline 2 mg tablet |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1524 |
Rasagiline mesilate |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
002 3件: 2 , 5 , 6 💬 |
1525 |
Rasagiline mesylate |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 2件: 6 , 17 💬 |
1526 |
Rasagiline mesylate 1.0 mg |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1527 |
Rasagiline mesylate plus mirapex |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1528 |
Rasagiline mesylate with levodopa |
Levodopa |
4件: D00059 D00059, D02562 D02562, D08469 D08469, D10829 D10829 💬 |
DRD1 6件: DRD1, DRD2, DRD3, DRD4, DRD5, MAOB 💬 |
Alcoholism 20件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1529 |
Rasagiline mesylate with requip |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1530 |
Rasagiline tablets |
Rasagiline |
3件: D02562 D02562, D08469 D08469, D10829 D10829 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1531 |
Recombinant human cerebral dopamine neurotrophic factor |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1532 |
Recombinant-methionyl human glial cell line-derived neurotrophic factor |
- |
- |
- |
- |
006 1件: 6 💬 |
1533 |
Reduced glutathione |
Glutathione |
2件: D00014 D00014, D00031 D00031 💬 |
- |
- |
006 2件: 6 , 299 💬 |
1534 |
Reduced glutathione 100mg |
Glutathione |
2件: D00014 D00014, D00031 D00031 💬 |
- |
- |
006 1件: 6 💬 |
1535 |
Reduced glutathione 200mg |
Glutathione |
2件: D00014 D00014, D00031 D00031 💬 |
- |
- |
006 1件: 6 💬 |
1536 |
Regular novolin r |
- |
- |
- |
- |
006 1件: 6 💬 |
1537 |
Remifentanil |
Remifentanil |
2件: D01177 D01177, D08473 D08473 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
006 2件: 6 , 70 💬 |
1538 |
Remifentanyl |
Remifentanil |
2件: D01177 D01177, D08473 D08473 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
1539 |
Reminyl |
- |
- |
- |
- |
006 1件: 6 💬 |
1540 |
Reminyl retard |
- |
- |
- |
- |
006 1件: 6 💬 |
1541 |
Repaglinide |
Repaglinide |
1件: D00594 D00594 💬 |
ABCC8 2件: ABCC8, KCNJ11 💬 |
ABC transporters 4件: ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus |
006 3件: 6 , 21, 299 💬 |
1542 |
Requip |
- |
- |
- |
- |
006 2件: 6 , 309 💬 |
1543 |
Requip 21 cpr 0,25 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1544 |
Requip 21 cpr 0,5 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1545 |
Requip 21 cpr 1 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1546 |
Requip 21 cpr 2 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1547 |
Requip cr |
- |
- |
- |
- |
002 2件: 2 , 6 💬 |
1548 |
Requip modutab, 2mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1549 |
Requip modutab, 4mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1550 |
Requip modutab, 8mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1551 |
Requip pr |
- |
- |
- |
- |
006 1件: 6 💬 |
1552 |
Requip prolonged release |
- |
- |
- |
- |
006 1件: 6 💬 |
1553 |
Requip xl prolonged-release |
- |
- |
- |
- |
006 1件: 6 💬 |
1554 |
Requip*21cpr 0,25mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1555 |
Requip*21cpr 0,5mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1556 |
Requip*21cpr 1mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1557 |
Requip*21cpr 5mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1558 |
Requip*28cpr 8mg r.p. |
- |
- |
- |
- |
006 1件: 6 💬 |
1559 |
Requip-lp |
- |
- |
- |
- |
006 1件: 6 💬 |
1560 |
Requip-modutab |
- |
- |
- |
- |
006 1件: 6 💬 |
1561 |
Requip-modutab , 2mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1562 |
Requip-modutab , 4mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1563 |
Requip-modutab , 8mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1564 |
Requip-modutab, 2mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1565 |
Requip-modutab, 4mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1566 |
Requip-modutab, 8mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1567 |
Resistant maltodextrin |
Maltodextrin |
1件: D02329 D02329 💬 |
- |
- |
006 1件: 6 💬 |
1568 |
Resistant starch |
- |
- |
- |
- |
006 1件: 6 💬 |
1569 |
Restex tabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
1570 |
Rifampicin |
Rifampicin |
1件: D00211 D00211 💬 |
- |
- |
006 5件: 6 , 17, 46, 93, 299 💬 |
1571 |
Rifampin |
Rifampicin |
1件: D00211 D00211 💬 |
- |
- |
006 5件: 6 , 13, 84, 86, 299 💬 |
1572 |
Rifampin 300mg bid + istradefylline 40mg day 8 only |
Istradefylline |
2件: D00211 D00211, D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
1573 |
Rifaximin |
Rifaximin |
1件: D02554 D02554 💬 |
- |
- |
006 6件: 6 , 65, 96, 97, 99, 296 💬 |
1574 |
Rifaximin 550 mg |
Rifaximin |
1件: D02554 D02554 💬 |
- |
- |
006 1件: 6 💬 |
1575 |
Ritalin |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
1576 |
Riv-tds 13.3 mg/24 h |
- |
- |
- |
- |
006 1件: 6 💬 |
1577 |
Rivastigmin luye transdermal patches - 4.6mg/24h |
- |
- |
- |
- |
006 1件: 6 💬 |
1578 |
Rivastigmine |
Rivastigmine |
2件: D02558 D02558, D03822 D03822 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
005 3件: 5 , 6 , 13 💬 |
1579 |
Rivastigmine capsule |
Rivastigmine |
2件: D02558 D02558, D03822 D03822 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
1580 |
Rivastigmine cf |
Rivastigmine |
2件: D02558 D02558, D03822 D03822 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
1581 |
Rivastigmine luye transdermal patch- 9.5mg/24h |
Rivastigmine |
2件: D02558 D02558, D03822 D03822 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
1582 |
Rivastigmine patch 9.5 cm2 |
Rivastigmine |
2件: D02558 D02558, D03822 D03822 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
1583 |
Rivastigmine transdermal patch |
Rivastigmine |
2件: D02558 D02558, D03822 D03822 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 2件: 6 , 13 💬 |
1584 |
Rivastigmine transdermal system |
Rivastigmine |
2件: D02558 D02558, D03822 D03822 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
1585 |
Rivastigmine transdermal system 13.3 mg/24 h |
Rivastigmine |
2件: D02558 D02558, D03822 D03822 💬 |
ACHE 1件: ACHE 💬 |
Cholinergic synapse 2件: Cholinergic synapse, Glycerophospholipid metabolism |
006 1件: 6 💬 |
1586 |
Rm-131 |
- |
- |
- |
- |
006 1件: 6 💬 |
1587 |
Ro |
- |
- |
- |
- |
006 1件: 6 💬 |
1588 |
Ro7046015 |
- |
- |
- |
- |
006 1件: 6 💬 |
1589 |
Rop |
- |
- |
- |
- |
006 1件: 6 💬 |
1590 |
Rop+l-dopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1591 |
Ropinirole |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 3件: 6 , 74, 309 💬 |
1592 |
Ropinirole (as hydrochloride) |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1593 |
Ropinirole controlled-release (requip cr) for rls |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1594 |
Ropinirole cr 2mg tablet |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1595 |
Ropinirole cr 8mg tablet |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1596 |
Ropinirole hydrochloride |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 2件: 6 , 309 💬 |
1597 |
Ropinirole hydrochloride extended-release tablet |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1598 |
Ropinirole hydrochloride extended-release tablet placebo |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1599 |
Ropinirole hydrochloride prolonged release |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1600 |
Ropinirole immediate release |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1601 |
Ropinirole implant |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1602 |
Ropinirole ir |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1603 |
Ropinirole ir tablets |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1604 |
Ropinirole monotherapy |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1605 |
Ropinirole oral product |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1606 |
Ropinirole pr |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1607 |
Ropinirole pr, 2mg |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1608 |
Ropinirole pr/xr |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1609 |
Ropinirole pr/xr tablets |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1610 |
Ropinirole prolonged release |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1611 |
Ropinirole prolonged release/extended release(pr/xr) |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1612 |
Ropinirole xl |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1613 |
Ropinirole xl (formerly cr) |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1614 |
Ropinirole/l-dopa |
Levodopa |
3件: D00059 D00059, D00784 D00784, D08489 D08489 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1615 |
Rosuvastatin |
Rosuvastatin |
2件: D01915 D01915, D08492 D08492 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
006 11件: 6 , 18, 46, 49, 51, 56, 79, 96, 97, 271, 299 💬 |
1616 |
Rotigotin |
- |
- |
- |
- |
006 1件: 6 💬 |
1617 |
Rotigotina |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1618 |
Rotigotine |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1619 |
Rotigotine (reference product pr 2.1.1) |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1620 |
Rotigotine (test product pr 2.3.1) |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1621 |
Rotigotine hydrochloride |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1622 |
Rotigotine nasal spray |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1623 |
Rotigotine transdermal patch |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1624 |
Rotigotine transdermal patch 2mg/24h(10cm2) |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1625 |
Rotigotine transdermal patch 4mg/24h (20cm2) |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1626 |
Rotigotine transdermal patch 6mg/24h (30cm2) |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1627 |
Rotigotine transdermal patch 8mg/24h (40cm2) |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1628 |
Rotigotine tts (test) |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1629 |
Rotigotine, extended-release microspheres |
Rotigotine |
1件: D05768 D05768 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1630 |
Rozerem |
- |
- |
- |
- |
006 1件: 6 💬 |
1631 |
Rq-00000010 |
- |
- |
- |
- |
006 1件: 6 💬 |
1632 |
Rvg 08740 |
- |
- |
- |
- |
006 1件: 6 💬 |
1633 |
Rvg 55618 |
- |
- |
- |
- |
006 1件: 6 💬 |
1634 |
Rvt-101 35 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1635 |
Rytary 145 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1636 |
Rytary 195 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1637 |
S 90049 |
- |
- |
- |
- |
006 1件: 6 💬 |
1638 |
S 90049 - f36 |
- |
- |
- |
- |
006 1件: 6 💬 |
1639 |
S 90049 - f38 |
- |
- |
- |
- |
006 1件: 6 💬 |
1640 |
S.c. apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1641 |
S90049 |
- |
- |
- |
- |
006 1件: 6 💬 |
1642 |
Sa |
- |
- |
- |
- |
006 5件: 6 , 30, 60, 118, 298 💬 |
1643 |
Safety observation |
- |
- |
- |
- |
006 1件: 6 💬 |
1644 |
Safinamida |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1645 |
Safinamide |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 2件: 6 , 17 💬 |
1646 |
Safinamide (as add-on therapy) |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1647 |
Safinamide + levodopa |
Levodopa |
2件: D00059 D00059, D10158 D10158 💬 |
DRD1 6件: DRD1, DRD2, DRD3, DRD4, DRD5, MAOB 💬 |
Alcoholism 20件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1648 |
Safinamide metansolfonato |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1649 |
Safinamide metansolfonato (12 weeks) |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1650 |
Safinamide methanesulfonate |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 2件: 6 , 17 💬 |
1651 |
Safinamide methanesulfonate 100mg |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1652 |
Safinamide methanesulfonate 150mg |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1653 |
Safinamide methansulfonate |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1654 |
Safinamide, mao-b inhibitor |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1655 |
Safinimide 50-100 mg/day |
- |
- |
- |
- |
006 1件: 6 💬 |
1656 |
Sage |
Sage |
- |
- |
- |
006 1件: 6 💬 |
1657 |
Sage leaf |
Sage |
- |
- |
- |
006 1件: 6 💬 |
1658 |
Sage-217 |
- |
- |
- |
- |
006 1件: 6 💬 |
1659 |
Sage-718 |
- |
- |
- |
- |
006 2件: 6 , 8 💬 |
1660 |
Saline |
- |
- |
- |
- |
006 10件: 6 , 13, 17, 53, 67, 78, 86, 97, 168, 299 💬 |
1661 |
Saline intranasal delivery |
- |
- |
- |
- |
006 1件: 6 💬 |
1662 |
Sam |
- |
- |
- |
- |
006 1件: 6 💬 |
1663 |
Sam-e |
Ademetionine |
1件: D07128 D07128 💬 |
- |
- |
006 1件: 6 💬 |
1664 |
Sar402671, gz402671 or gz/sar402671 |
- |
- |
- |
- |
006 3件: 6 , 19, 67 💬 |
1665 |
Saracatinib |
Saracatinib |
1件: D09664 D09664 💬 |
ABL1 2件: ABL1, SRC 💬 |
Adherens junction 46件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection |
006 3件: 6 , 89, 272 💬 |
1666 |
Sarcosine |
Sarcosine |
- |
- |
- |
006 1件: 6 💬 |
1667 |
Sarcosine capsule |
Sarcosine |
- |
- |
- |
006 1件: 6 💬 |
1668 |
Sargramostim |
Sargramostim |
1件: D05803 D05803 💬 |
CSF2RA 1件: CSF2RA 💬 |
Cytokine-cytokine receptor interaction 4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
006 7件: 6 , 28, 60, 62, 96, 229, 285 💬 |
1669 |
Sarizotan |
Sarizotan |
- |
- |
- |
006 2件: 6 , 156 💬 |
1670 |
Sarizotan hc1 |
Sarizotan |
- |
- |
- |
006 1件: 6 💬 |
1671 |
Sarizotan hcl |
Sarizotan |
- |
- |
- |
006 1件: 6 💬 |
1672 |
Sarizotan hydrochloride |
Sarizotan |
- |
- |
- |
006 2件: 6 , 156 💬 |
1673 |
Sch 420814 |
- |
- |
- |
- |
006 1件: 6 💬 |
1674 |
Sch 420814 10 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1675 |
Sch 420814 100 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1676 |
Sch 900800 |
- |
- |
- |
- |
006 1件: 6 💬 |
1677 |
Sch420814 |
- |
- |
- |
- |
006 1件: 6 💬 |
1678 |
Selegiline |
Selegiline |
2件: D00785 D00785, D03731 D03731 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1679 |
Selegiline hcl 5 pch |
Selegiline |
2件: D00785 D00785, D03731 D03731 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1680 |
Semaglutide |
Semaglutide |
1件: D10025 D10025 💬 |
GLP1R 1件: GLP1R 💬 |
Insulin secretion 3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
006 1件: 6 💬 |
1681 |
Semi continuous intra-oral administration of ld/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
1682 |
Sep-363856 |
SEP-363856 |
- |
- |
- |
006 1件: 6 💬 |
1683 |
Ser-214 |
- |
- |
- |
- |
006 1件: 6 💬 |
1684 |
Serine |
Serine |
1件: D00016 D00016 💬 |
- |
- |
002 3件: 2 , 6 , 86 💬 |
1685 |
Seroquel |
- |
- |
- |
- |
006 1件: 6 💬 |
1686 |
Sertraline |
Sertraline |
2件: D00825 D00825, D02360 D02360 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6 , 206 💬 |
1687 |
Sevoflurane |
Sevoflurane |
1件: D00547 D00547 💬 |
- |
- |
006 6件: 6 , 21, 22, 34, 98, 296 💬 |
1688 |
Sifol |
- |
- |
- |
- |
006 1件: 6 💬 |
1689 |
Sifrol |
- |
- |
- |
- |
006 1件: 6 💬 |
1690 |
Sifrol 0,088 |
- |
- |
- |
- |
006 1件: 6 💬 |
1691 |
Sifrol 0,18 |
- |
- |
- |
- |
006 1件: 6 💬 |
1692 |
Sifrol 0,35 |
- |
- |
- |
- |
006 1件: 6 💬 |
1693 |
Sifrol 0,7 |
- |
- |
- |
- |
006 1件: 6 💬 |
1694 |
Sifrol, 0,35 mg tablette |
- |
- |
- |
- |
006 1件: 6 💬 |
1695 |
Sifrol, 0,70 mg tablette |
- |
- |
- |
- |
006 1件: 6 💬 |
1696 |
Sifrol, mirapexin |
- |
- |
- |
- |
006 1件: 6 💬 |
1697 |
Sifrol® |
- |
- |
- |
- |
006 1件: 6 💬 |
1698 |
Sildenafil |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
006 17件: 6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬 |
1699 |
Silicon |
Silicon |
- |
- |
- |
006 1件: 6 💬 |
1700 |
Silodosin |
Silodosin |
1件: D01965 D01965 💬 |
ADRA1A 1件: ADRA1A 💬 |
AMPK signaling pathway 7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1701 |
Simvastatin |
Simvastatin |
1件: D00434 D00434 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
006 21件: 6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬 |
1702 |
Simvastatine |
Simvastatin |
1件: D00434 D00434 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
006 3件: 6 , 13, 288 💬 |
1703 |
Sinemet |
- |
- |
- |
- |
006 1件: 6 💬 |
1704 |
Sinemet (carbidopa/levodopa) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1705 |
Sinemet (comparator) |
- |
- |
- |
- |
006 1件: 6 💬 |
1706 |
Sinemet (levodopa/carbidopa) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1707 |
Sinemet 10-100 |
- |
- |
- |
- |
006 1件: 6 💬 |
1708 |
Sinemet 100 mg + 25 mg compresse |
- |
- |
- |
- |
006 1件: 6 💬 |
1709 |
Sinemet 125 |
- |
- |
- |
- |
006 1件: 6 💬 |
1710 |
Sinemet 125 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1711 |
Sinemet 200mg/50mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1712 |
Sinemet 25-100 |
- |
- |
- |
- |
006 1件: 6 💬 |
1713 |
Sinemet 25/100 |
- |
- |
- |
- |
006 1件: 6 💬 |
1714 |
Sinemet cr |
- |
- |
- |
- |
006 1件: 6 💬 |
1715 |
Sinemet cr 25mg-100mg extended-release tablet |
- |
- |
- |
- |
006 1件: 6 💬 |
1716 |
Sinemet ir |
- |
- |
- |
- |
006 1件: 6 💬 |
1717 |
Sinemet plus |
- |
- |
- |
- |
006 1件: 6 💬 |
1718 |
Sinemet plus (levodopa/carbidopa) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1719 |
Sinemet*50cpr 100mg+25mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1720 |
Sinemet-plus tablets |
- |
- |
- |
- |
006 1件: 6 💬 |
1721 |
Sinemet® |
- |
- |
- |
- |
006 1件: 6 💬 |
1722 |
Sinemet® 100/25 |
- |
- |
- |
- |
006 1件: 6 💬 |
1723 |
Sinemet® 100/25 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1724 |
Sinemet® controlled release (carbidopa/levodopa) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1725 |
Sinemet® cr |
- |
- |
- |
- |
006 1件: 6 💬 |
1726 |
Sinemet® cr 100/25 |
- |
- |
- |
- |
006 1件: 6 💬 |
1727 |
Sinemet® plus 25 mg/100 mg tablets |
- |
- |
- |
- |
006 1件: 6 💬 |
1728 |
Sinemet®-plus tablets |
- |
- |
- |
- |
006 1件: 6 💬 |
1729 |
Sinemet®25-100 |
- |
- |
- |
- |
006 1件: 6 💬 |
1730 |
Sirio*30cpr eff 25mg+100mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1731 |
Sirolimus |
Sirolimus |
1件: D00753 D00753 💬 |
MTOR 1件: MTOR 💬 |
AMPK signaling pathway 50件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
006 35件: 6 , 13, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 💬 |
1732 |
Sitagliptin |
Sitagliptin |
1件: D08516 D08516 💬 |
DPP4 1件: DPP4 💬 |
Protein digestion and absorption 1件: Protein digestion and absorption |
006 4件: 6 , 75, 233, 299 💬 |
1733 |
Sk&f101468 |
- |
- |
- |
- |
006 1件: 6 💬 |
1734 |
Skf-101468a |
- |
- |
- |
- |
006 1件: 6 💬 |
1735 |
Slv308 |
- |
- |
- |
- |
006 1件: 6 💬 |
1736 |
Slv308 (mono) hydro |
- |
- |
- |
- |
006 1件: 6 💬 |
1737 |
Slv308 (mono) hydrochlo |
- |
- |
- |
- |
006 1件: 6 💬 |
1738 |
Slv308 (mono) hydrochlori |
- |
- |
- |
- |
006 1件: 6 💬 |
1739 |
Slv308 (mono) hydrochloride |
- |
- |
- |
- |
006 1件: 6 💬 |
1740 |
Slv308 (mono)hydrochloride |
- |
- |
- |
- |
006 1件: 6 💬 |
1741 |
Slv308 hydrochloride |
- |
- |
- |
- |
006 1件: 6 💬 |
1742 |
Slv308(mono)hydrochloride |
- |
- |
- |
- |
006 1件: 6 💬 |
1743 |
Smilagenin |
Smilagenin |
- |
- |
- |
006 1件: 6 💬 |
1744 |
Snd 919 cl2 y |
- |
- |
- |
- |
006 1件: 6 💬 |
1745 |
Snd 919 cl2y |
- |
- |
- |
- |
006 1件: 6 💬 |
1746 |
Snn0031 |
- |
- |
- |
- |
006 1件: 6 💬 |
1747 |
Sodium chloride |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
006 20件: 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 168, 193, 227, 228, 271, 288, 299 💬 |
1748 |
Sodium oxybate |
Sodium oxybate |
1件: D05866 D05866 💬 |
- |
- |
006 2件: 6 , 149 💬 |
1749 |
Solifenacin |
Solifenacin |
2件: D01269 D01269, D08522 D08522 💬 |
CHRM3 1件: CHRM3 💬 |
Alzheimer disease 11件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
006 2件: 6 , 13 💬 |
1750 |
Solifenacin succinate (vesicare) |
Solifenacin |
2件: D01269 D01269, D08522 D08522 💬 |
CHRM3 1件: CHRM3 💬 |
Alzheimer disease 11件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
006 1件: 6 💬 |
1751 |
Soligen |
- |
- |
- |
- |
006 1件: 6 💬 |
1752 |
Solu-cortef |
- |
- |
- |
- |
006 3件: 6 , 81, 83 💬 |
1753 |
Solu-cortef, powder for solution for injection, 100mg, and 'act-o-vial' |
- |
- |
- |
- |
006 1件: 6 💬 |
1754 |
Sorbitol |
Sorbitol |
1件: D00096 D00096 💬 |
- |
- |
006 2件: 6 , 10 💬 |
1755 |
Soy protein |
- |
- |
- |
- |
006 2件: 6 , 96 💬 |
1756 |
Spect |
- |
- |
- |
- |
006 1件: 6 💬 |
1757 |
Spheramine (bay86-5280) |
- |
- |
- |
- |
006 1件: 6 💬 |
1758 |
Spiropent |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
1759 |
Spm 926 |
- |
- |
- |
- |
006 1件: 6 💬 |
1760 |
Spm 962 |
- |
- |
- |
- |
006 1件: 6 💬 |
1761 |
Spm962 |
- |
- |
- |
- |
006 1件: 6 💬 |
1762 |
Sqjz herbal mixtures |
- |
- |
- |
- |
006 1件: 6 💬 |
1763 |
Sr57667b |
- |
- |
- |
- |
006 1件: 6 💬 |
1764 |
Stalevo |
- |
- |
- |
- |
006 1件: 6 💬 |
1765 |
Stalevo (levodopa/ carbidopa/ entacapone) |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1766 |
Stalevo (levodopa/carbidopa/entacapona) |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1767 |
Stalevo (levodopa/carbidopa/entacapone) |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1768 |
Stalevo 100 |
- |
- |
- |
- |
006 1件: 6 💬 |
1769 |
Stalevo 100 mg/ 25 mg/ 200 mg filmtabletten |
- |
- |
- |
- |
006 1件: 6 💬 |
1770 |
Stalevo 100 mg/25 mg / 200 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1771 |
Stalevo 100/25/200 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1772 |
Stalevo 150 |
- |
- |
- |
- |
006 1件: 6 💬 |
1773 |
Stalevo 150/37.5/200 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1774 |
Stalevo*100cpr 100/25/200mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1775 |
Stalevo*100cpr 50/12,5/200mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1776 |
Stalevo® |
- |
- |
- |
- |
006 1件: 6 💬 |
1777 |
Standard ld/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
1778 |
Standard of care |
- |
- |
- |
- |
006 12件: 6 , 13, 14, 46, 49, 51, 63, 64, 79, 85, 158, 271 💬 |
1779 |
Stilnoct |
- |
- |
- |
- |
006 1件: 6 💬 |
1780 |
Strattera |
- |
- |
- |
- |
006 1件: 6 💬 |
1781 |
Study drug |
- |
- |
- |
- |
006 2件: 6 , 13 💬 |
1782 |
Subcutaneous apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1783 |
Subcutaneous hydrocortisone 10mg |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
1784 |
Subjects will undergo the 123-i ibvm imaging visit |
- |
- |
- |
- |
006 1件: 6 💬 |
1785 |
Sugar pill |
- |
- |
- |
- |
005 8件: 5 , 6 , 49, 67, 70, 86, 206, 210 💬 |
1786 |
Sulfate |
Sulfate ion |
- |
- |
- |
002 25件: 2 , 6 , 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 79, 85, 86, 96, 111, 222, 226, 265, 296, 297, 299 💬 |
1787 |
Sumanirole |
Sumanirole |
- |
- |
- |
006 1件: 6 💬 |
1788 |
Supplementation |
- |
- |
- |
- |
006 1件: 6 💬 |
1789 |
Supressi. t-diet plus range |
- |
- |
- |
- |
006 1件: 6 💬 |
1790 |
Suvorexant |
Suvorexant |
1件: D10082 D10082 💬 |
HCRTR1 2件: HCRTR1, HCRTR2 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
005 3件: 5 , 6 , 13 💬 |
1791 |
Syn115 |
- |
- |
- |
- |
006 1件: 6 💬 |
1792 |
Syn115 tablets, 60 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1793 |
Syn120 |
- |
- |
- |
- |
006 1件: 6 💬 |
1794 |
Synthetic oxytocin |
Oxytocin |
1件: D00089 D00089 💬 |
OXTR 1件: OXTR 💬 |
Calcium signaling pathway 4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1795 |
Syntocinon |
- |
- |
- |
- |
006 3件: 6 , 127, 193 💬 |
1796 |
Syntocinon 40 iu/ml nasal spray |
- |
- |
- |
- |
006 1件: 6 💬 |
1797 |
Tacrolimus |
Tacrolimus |
2件: D00107 D00107, D08556 D08556 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
002 32件: 2 , 6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬 |
1798 |
Tacrolimus tablets |
Tacrolimus |
2件: D00107 D00107, D08556 D08556 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1799 |
Tadalafil |
Tadalafil |
1件: D02008 D02008 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
006 7件: 6 , 51, 75, 84, 86, 113, 210 💬 |
1800 |
Tak-071 |
- |
- |
- |
- |
006 1件: 6 💬 |
1801 |
Talampanel |
Talampanel |
1件: D02696 D02696 💬 |
GRIA1 4件: GRIA1, GRIA2, GRIA3, GRIA4 💬 |
Amphetamine addiction 16件: Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway |
002 2件: 2 , 6 💬 |
1802 |
Targinact 10 mg/5 mg prolonged-release tablets |
- |
- |
- |
- |
006 2件: 6 , 226 💬 |
1803 |
Targinact 20 mg/10 mg prolonged-release tablets |
- |
- |
- |
- |
006 1件: 6 💬 |
1804 |
Targinact 5 mg/2.5 mg prolonged-release tablets |
- |
- |
- |
- |
006 1件: 6 💬 |
1805 |
Tasmar |
- |
- |
- |
- |
006 2件: 6 , 28 💬 |
1806 |
Tavapadon |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1807 |
Tavapadon 0.25mg |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1808 |
Tavapadon 1mg |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1809 |
Tavapadon 5mg |
Tavapadon |
1件: D11431 D11431 💬 |
DRD1 2件: DRD1, DRD5 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
006 1件: 6 💬 |
1810 |
Tce |
- |
- |
- |
- |
006 1件: 6 💬 |
1811 |
Tch346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt) |
Hydrogen |
- |
- |
- |
006 1件: 6 💬 |
1812 |
Td-9855 |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
1813 |
Technetium (99mtc) exametazime |
Exametazime |
1件: D01109 D01109 💬 |
- |
- |
006 1件: 6 💬 |
1814 |
Terazosin |
Terazosin |
2件: D00610 D00610, D08569 D08569 💬 |
ADRA1A 3件: ADRA1A, ADRA1B, ADRA1D 💬 |
AMPK signaling pathway 7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1815 |
Terazosin 5 mg |
Terazosin |
2件: D00610 D00610, D08569 D08569 💬 |
ADRA1A 3件: ADRA1A, ADRA1B, ADRA1D 💬 |
AMPK signaling pathway 7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1816 |
Tesofensine |
Tesofensine |
- |
- |
- |
006 2件: 6 , 193 💬 |
1817 |
Thn02 |
- |
- |
- |
- |
006 1件: 6 💬 |
1818 |
Thn102 dosage a |
- |
- |
- |
- |
006 1件: 6 💬 |
1819 |
Thn102 dosage b |
- |
- |
- |
- |
006 1件: 6 💬 |
1820 |
Thn102 dosage c |
- |
- |
- |
- |
006 1件: 6 💬 |
1821 |
Tigan |
- |
- |
- |
- |
006 1件: 6 💬 |
1822 |
Tigan® |
- |
- |
- |
- |
006 1件: 6 💬 |
1823 |
To |
- |
- |
- |
- |
006 1件: 6 💬 |
1824 |
Tocovid suprabio |
- |
- |
- |
- |
006 1件: 6 💬 |
1825 |
Tolcapon |
Tolcapone |
1件: D00786 D00786 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
1826 |
Tolcapone |
Tolcapone |
1件: D00786 D00786 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 3件: 6 , 28, 127 💬 |
1827 |
Tolubuterol hydrochloride |
- |
- |
- |
- |
006 1件: 6 💬 |
1828 |
Topiramate |
Topiramate |
1件: D00537 D00537 💬 |
CA2 36件: CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 52件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Arrhythmogenic right ventricular cardiomyopathy, Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 5件: 6 , 140, 144, 156, 193 💬 |
1829 |
Topiramate (drug) |
Topiramate |
1件: D00537 D00537 💬 |
CA2 36件: CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 52件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Arrhythmogenic right ventricular cardiomyopathy, Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1830 |
Toz |
- |
- |
- |
- |
006 1件: 6 💬 |
1831 |
Tozadenant |
Tozadenant |
1件: D10174 D10174 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
1832 |
Tozadenant (syn115) 120 mg bid |
Tozadenant |
1件: D10174 D10174 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
1833 |
Tozadenant (syn115) 180 mg bid |
Tozadenant |
1件: D10174 D10174 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
1834 |
Tozadenant (syn115) 240 mg bid |
Tozadenant |
1件: D10174 D10174 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
1835 |
Tozadenant (syn115) 60 mg bid |
Tozadenant |
1件: D10174 D10174 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
1836 |
Traditional chinese medicinal mixture (composed of roucongrong and adjuvant) |
- |
- |
- |
- |
006 1件: 6 💬 |
1837 |
Transdermal flumazenil (added 4/2020) |
Flumazenil |
1件: D00697 D00697 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 1件: 6 💬 |
1838 |
Transdermal nicotine |
Nicotine |
3件: D03365 D03365, D05156 D05156, D05157 D05157 💬 |
CHRNA1 16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 |
Alzheimer disease 7件: Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases |
006 1件: 6 💬 |
1839 |
Trigel |
- |
- |
- |
- |
006 1件: 6 💬 |
1840 |
Trihexyphenidyl |
Trihexyphenidyl |
2件: D00787 D00787, D08638 D08638 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
005 2件: 5 , 6 💬 |
1841 |
Trimethobenzamide |
Trimethobenzamide |
2件: D02733 D02733, D08643 D08643 💬 |
- |
- |
006 1件: 6 💬 |
1842 |
Trimethobenzamide hydrochloride |
Trimethobenzamide |
2件: D02733 D02733, D08643 D08643 💬 |
- |
- |
006 1件: 6 💬 |
1843 |
Trivastal |
- |
- |
- |
- |
006 1件: 6 💬 |
1844 |
Tropicamide |
Tropicamide |
1件: D00397 D00397 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 2件: 6 , 19 💬 |
1845 |
Tryptophan |
Tryptophan |
1件: D00020 D00020 💬 |
- |
- |
006 1件: 6 💬 |
1846 |
Tryptophan (trp) depletion |
Tryptophan |
1件: D00020 D00020 💬 |
- |
- |
006 1件: 6 💬 |
1847 |
Tulobuterol |
Tulobuterol |
1件: D02151 D02151 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1848 |
Tulobuterol hydrochloride |
Tulobuterol |
1件: D02151 D02151 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1849 |
Tvp-1012 |
- |
- |
- |
- |
006 1件: 6 💬 |
1850 |
Tvp-1012 (1 mg/day) with levodopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1851 |
Tvp-1012 0.5mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1852 |
Tvp-1012 1mg |
- |
- |
- |
- |
006 1件: 6 💬 |
1853 |
Tyramine |
Tyramine |
- |
- |
- |
006 1件: 6 💬 |
1854 |
Tyrosine |
Tyrosine |
1件: D00022 D00022 💬 |
- |
- |
006 3件: 6 , 86, 111 💬 |
1855 |
Ub-312 |
- |
- |
- |
- |
006 1件: 6 💬 |
1856 |
Ubiquinol |
Ubiquinol |
- |
- |
- |
006 3件: 6 , 8 , 17 💬 |
1857 |
Ucb0599 |
- |
- |
- |
- |
006 1件: 6 💬 |
1858 |
Ucb7853 |
- |
- |
- |
- |
006 1件: 6 💬 |
1859 |
Urate |
Uric acid |
- |
- |
- |
006 1件: 6 💬 |
1860 |
Ursodeoxycholic acid |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
006 8件: 6 , 67, 84, 93, 94, 95, 96, 97 💬 |
1861 |
Ursonorm |
- |
- |
- |
- |
006 1件: 6 💬 |
1862 |
Usual dopaminergic per os treatment |
- |
- |
- |
- |
006 1件: 6 💬 |
1863 |
V1512 |
- |
- |
- |
- |
006 1件: 6 💬 |
1864 |
V1512 and entacapone |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
1865 |
V81444 |
- |
- |
- |
- |
006 1件: 6 💬 |
1866 |
Valerian |
Valerian |
- |
- |
- |
006 1件: 6 💬 |
1867 |
Varenicline |
Varenicline |
1件: D08669 D08669 💬 |
CHRNA4 2件: CHRNA4, CHRNB2 💬 |
Cholinergic synapse 3件: Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
006 2件: 6 , 18 💬 |
1868 |
Varenicline tartrate |
Varenicline |
1件: D08669 D08669 💬 |
CHRNA4 2件: CHRNA4, CHRNB2 💬 |
Cholinergic synapse 3件: Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
006 1件: 6 💬 |
1869 |
Variation of behaviors of parkinson's disease |
- |
- |
- |
- |
006 1件: 6 💬 |
1870 |
Vehicle |
- |
- |
- |
- |
006 4件: 6 , 36, 160, 192 💬 |
1871 |
Venglustat |
Venglustat |
1件: D11633 D11633 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
006 3件: 6 , 19, 67 💬 |
1872 |
Venglustat malate |
Venglustat |
1件: D11633 D11633 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
006 1件: 6 💬 |
1873 |
Venlafaxine |
Venlafaxine |
2件: D00821 D00821, D08670 D08670 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 3件: 6 , 13, 46 💬 |
1874 |
Vineuro |
- |
- |
- |
- |
006 1件: 6 💬 |
1875 |
Vitamin b12 |
Cyanocobalamin |
4件: D00166 D00166, D03615 D03615, D03616 D03616, D03617 D03617 💬 |
- |
- |
006 4件: 6 , 201, 229, 299 💬 |
1876 |
Vitamin b12 supplementation |
Cyanocobalamin |
4件: D00166 D00166, D03615 D03615, D03616 D03616, D03617 D03617 💬 |
- |
- |
006 1件: 6 💬 |
1877 |
Vitamin b6 |
Pyridoxine |
2件: D02179 D02179, D08454 D08454 💬 |
- |
- |
006 1件: 6 💬 |
1878 |
Vitamin d3 |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
006 11件: 6 , 13, 20, 46, 49, 53, 60, 65, 96, 97, 299 💬 |
1879 |
Vitamin d3 - high dose |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
006 1件: 6 💬 |
1880 |
Vitamin e |
Vitamin E |
1件: D02331 D02331 💬 |
- |
- |
002 11件: 2 , 6 , 13, 20, 46, 90, 96, 97, 206, 299, 317 💬 |
1881 |
Viusid/alzer |
- |
- |
- |
- |
006 1件: 6 💬 |
1882 |
Vortioxetine |
Vortioxetine |
1件: D10184 D10184 💬 |
HTR1A 7件: HTR1A, HTR3A, HTR3B, HTR3C, HTR3D, HTR3E, SLC6A4 💬 |
Neuroactive ligand-receptor interaction 5件: Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
1883 |
Vr040 |
- |
- |
- |
- |
006 1件: 6 💬 |
1884 |
Vr040/aspirair® inhaler |
- |
- |
- |
- |
006 1件: 6 💬 |
1885 |
Vy-aadc01 |
- |
- |
- |
- |
006 1件: 6 💬 |
1886 |
Vy-aadc02 |
- |
- |
- |
- |
006 1件: 6 💬 |
1887 |
Warfarin |
Warfarin |
3件: D00564 D00564, D01280 D01280, D08682 D08682 💬 |
NQO1 2件: NQO1, VKORC1 💬 |
Biosynthesis of cofactors 6件: Biosynthesis of cofactors, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
006 11件: 6 , 8 , 13, 19, 46, 49, 66, 85, 88, 96, 97 💬 |
1888 |
Water |
Water |
1件: D00001 D00001 💬 |
- |
- |
002 22件: 2 , 5 , 6 , 13, 17, 19, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 💬 |
1889 |
Wd-1603 |
- |
- |
- |
- |
006 1件: 6 💬 |
1890 |
Wd-1603 carbidopa and levodopa extended-release tablets |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1891 |
Wd-1603 carbidopa/levodopa extended-release tablets |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1892 |
Whey protein |
- |
- |
- |
- |
006 2件: 6 , 96 💬 |
1893 |
White chocolate (0% cocoa) |
Cocoa |
- |
- |
- |
006 1件: 6 💬 |
1894 |
Win-1001x |
- |
- |
- |
- |
006 1件: 6 💬 |
1895 |
Wuling powder |
- |
- |
- |
- |
006 1件: 6 💬 |
1896 |
Xadago |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
1897 |
Xadago (safinamide) |
Safinamide |
1件: D10158 D10158 💬 |
MAOB 1件: MAOB 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1898 |
Xc130-a10h |
- |
- |
- |
- |
006 1件: 6 💬 |
1899 |
Xeomin |
- |
- |
- |
- |
005 7件: 5 , 6 , 7 , 13, 15, 17, 113 💬 |
1900 |
Xiaoyao pill |
- |
- |
- |
- |
006 1件: 6 💬 |
1901 |
Xp21279 |
- |
- |
- |
- |
006 1件: 6 💬 |
1902 |
Xp21279 and carbidopa (experimental) |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
1903 |
Yohimbine |
Yohimbine |
1件: D08685 D08685 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1904 |
Yohimbine hcl |
Yohimbine |
1件: D08685 D08685 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
1905 |
Zelapar |
- |
- |
- |
- |
006 1件: 6 💬 |
1906 |
Zoledronic acid |
Zoledronic acid |
4件: D01968 D01968, D06378 D06378, D06379 D06379, D08689 D08689 💬 |
FDPS 1件: FDPS 💬 |
Human T-cell leukemia virus 1 infection 4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
006 9件: 6 , 13, 46, 93, 95, 96, 274, 299, 333 💬 |
1907 |
Zoledronic acid 5mg/bag 100ml inj |
Zoledronic acid |
4件: D01968 D01968, D06378 D06378, D06379 D06379, D08689 D08689 💬 |
FDPS 1件: FDPS 💬 |
Human T-cell leukemia virus 1 infection 4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
006 1件: 6 💬 |
1908 |
Zolmitriptan |
Zolmitriptan |
1件: D00415 D00415 💬 |
HTR1B 2件: HTR1B, HTR1D 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
1909 |
Zolpidem |
Zolpidem |
2件: D00706 D00706, D08690 D08690 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
005 3件: 5 , 6 , 46 💬 |
1910 |
Zolpidem first dose |
Zolpidem |
2件: D00706 D00706, D08690 D08690 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 1件: 6 💬 |
1911 |
Zolpidem second dose |
Zolpidem |
2件: D00706 D00706, D08690 D08690 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 1件: 6 💬 |
1912 |
Zolpidem tartrate |
Zolpidem |
2件: D00706 D00706, D08690 D08690 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 1件: 6 💬 |
1913 |
Zonegran |
- |
- |
- |
- |
006 1件: 6 💬 |
1914 |
Zonisamide |
Zonisamide |
1件: D00538 D00538 💬 |
CACNA1G 8件: CACNA1G, CACNA1H, CACNA1I, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 11件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dopaminergic synapse, GnRH secretion, MAPK signaling pathway, Taste transduction, Type II diabetes mellitus |
006 1件: 6 💬 |
1915 |
Zonisamide capsules |
Zonisamide |
1件: D00538 D00538 💬 |
CACNA1G 8件: CACNA1G, CACNA1H, CACNA1I, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 11件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dopaminergic synapse, GnRH secretion, MAPK signaling pathway, Taste transduction, Type II diabetes mellitus |
006 1件: 6 💬 |
1916 |
Zopiclone |
Zopiclone |
1件: D01372 D01372 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 1件: 6 💬 |